<SEC-DOCUMENT>0001193125-21-320242.txt : 20211104
<SEC-HEADER>0001193125-21-320242.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104164428
ACCESSION NUMBER:		0001193125-21-320242
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211102
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TEVA PHARMACEUTICAL INDUSTRIES LTD
		CENTRAL INDEX KEY:			0000818686
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-16174
		FILM NUMBER:		211380596

	BUSINESS ADDRESS:	
		STREET 1:		5 BAZEL ST
		STREET 2:		P O B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
		BUSINESS PHONE:		9729267267

	MAIL ADDRESS:	
		STREET 1:		TEVA PHARMACEUTICAL INDUSTRIES LIMITED
		STREET 2:		5 BAZEL ST PO B 3190
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			49131
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d599039d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:teva="http://www.tevapharm.com/20211102" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2021-11-02_to_2021-11-02">TEVA PHARMACEUTICAL INDUSTRIES LTD</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityAddressCountry" name="dei:EntityAddressCountry" contextRef="duration_2021-11-02_to_2021-11-02">IL</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityTaxIdentificationNumber" name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-11-02_to_2021-11-02">00-0000000</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-11-02_to_2021-11-02">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-11-02_to_2021-11-02">0000818686</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="teva-20211102.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-11-02_to_2021-11-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818686</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-11-02</xbrli:startDate> <xbrli:endDate>2021-11-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-11-02_to_2021-11-02">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported) <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt:datemonthdayyearen">November&#160;2, 2021</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt-sec:edgarprovcountryen">Israel</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-11-02_to_2021-11-02">001-16174</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"> <span style=" -sec-ix-hidden:Hidden_dei_EntityTaxIdentificationNumber">Not Applicable</span> </span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other Jurisdiction of</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Incorporation Or Organization)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification Number)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-11-02_to_2021-11-02">124 Dvora Hanevi&#8217;a Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-11-02_to_2021-11-02">Tel Aviv</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-11-02_to_2021-11-02">6944020</ix:nonNumeric>, <span style=" -sec-ix-hidden:Hidden_dei_EntityAddressCountry">Israel</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of Principal Executive Offices, including Zip Code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">+<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-11-02_to_2021-11-02">972</ix:nonNumeric>- <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-11-02_to_2021-11-02">3-914-8213</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s Telephone Number, including Area Code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name, former address and former fiscal year, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Pre-commencement communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-11-02_to_2021-11-02">American Depositary Shares, each representing one Ordinary Share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-11-02_to_2021-11-02">TEVA</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">((&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging Growth Company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-11-02_to_2021-11-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;7.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Regulation FD&#160;Disclosure. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;2, 2021, Teva Pharmaceutical Industries Limited (the &#8220;Company&#8221;) issued a press release announcing the pricing of the Securities (as defined below). A copy of the related press release issued by the Company is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and incorporated herein in its entirety. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this Item 7.01 and Exhibit 99.1 hereto is being furnished to the Securities and Exchange Commission (the &#8220;Commission&#8221;) and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) nor shall it be deemed incorporated by reference in any filing made by the Company under the&#160;Securities Act&#160;or the Exchange Act, except as set forth by specific reference in such filing. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">On November&#160;2, 2021, Teva Pharmaceutical Finance Netherlands II B.V. (&#8220;Teva Finance II&#8221;), Teva Pharmaceutical Finance Netherlands III B.V. (&#8220;Teva Finance III&#8221; and together with Teva Finance II, the &#8220;Issuers&#8221;) and, the Company, as guarantor, entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with BNP Paribas, BNP Paribas Securities Corp., BofA Securities Europe SA, BofA Securities Inc., HSBC Bank plc and J.P. Morgan AG, as representatives for the underwriters named in Schedule 1 annexed thereto (the &#8220;Underwriters&#8221;), providing for the offer and sale by Teva Finance II of &#8364;1,100,000,000&#160;aggregate principal amount of 3.750% Sustainability-Linked Senior Notes due 2027 (the &#8220;2027 Euro Notes&#8221;) and &#8364;1,500,000,000&#160;aggregate principal amount of 4.375% Sustainability-Linked Senior Notes due 2030 (the &#8220;2030 Euro Notes&#8221;) and providing for the offer and sale by Teva Finance III of $1,000,000,000&#160;aggregate principal amount of 4.750% Sustainability-Linked Senior Notes due 2027 (the &#8220;2027 USD Notes&#8221;) and $1,100,000,000 aggregate principal amount of 5.125% Sustainability-Linked Senior Notes due 2029 (the &#8220;2029 USD Notes&#8221; and, together with the 2027 USD Notes, the 2030 Euro Notes and the 2027 Euro Notes, the &#8220;Securities&#8221;). The sale of the Securities is expected to close on November&#160;9, 2021. The offering of the 2027 Euro Notes was priced at 100.00% of the &#8364;1,1000,000,000&#160;principal amount of the 2027 Euro Notes to be issued. The offering of the 2030 Euro Notes was priced at 100.00% of the &#8364;1,5000,000,000 principal amount of the 2030 Euro Notes to be issued. The offering of the 2027 USD Notes was priced at 100.00% of the $1,0000,000,000&#160;principal amount of the 2027 USD Notes to be issued. The offering of the 2029 USD Notes was priced at 100.00% of the $1,0000,000,000&#160;principal amount of the 2029 USD Notes to be issued. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The offering of the Securities was registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and is being made pursuant to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-3ASR</span> (File No.&#160;333-260519) and the prospectus included therein (the &#8220;Registration Statement&#8221;), filed by the Company with the Commission on October&#160;27, 2021, and the prospectus supplement relating thereto, dated October 27, 2021, and filed with the Commission on October&#160;27, 2021 pursuant to Rule 424(b)(3) promulgated under the Securities Act. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and the Issuers. It also provides for customary indemnification by each of the Company, the Issuers and the Underwriters against certain liabilities and customary contribution provisions in respect of those liabilities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of the dates specified therein, were solely for the benefit of the parties thereto and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company and its subsidiaries. Moreover, information concerning the subject matter of any representations, warranties and covenants may change after the dates of the Underwriting Agreement, which subsequent information may or may not be fully reflected in public disclosures by the Company. Certain of the financial institutions party to the Underwriting Agreement, either directly or through affiliates, have performed, and may in the future perform, various commercial banking, investment banking and other financial advisory services in the ordinary course of business for the Company for which they have received, and will receive, customary fees and commissions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The foregoing description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to the copy thereof which is filed herewith as Exhibit&#160;1.1 and incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d599039dex11.htm">Underwriting Agreement, dated as of November&#160;2, 2021, among the Issuers, the Company, BNP Paribas, BNP Paribas Securities Corp., BofA Securities Europe SA, BofA Securities, Inc., HSBC Bank plc and J.P. Morgan AG, as representatives for the underwriters named in Schedule 1 annexed thereto. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d599039dex991.htm">Press Release dated November&#160;2, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The cover page of this Current Report on Form <span style="white-space:nowrap">8-K,</span> formatted in Inline XBRL.</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: November&#160;4, 2021 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:87%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">TEVA PHARMACEUTICAL INDUSTRIES LIMITED</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Eli Kalif</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Eli Kalif</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Executive Vice President, Chief Financial Officer</td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d599039dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;1,100,000,000 3.750% Sustainability-Linked Senior Notes due 2027 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;1,500,000,000 4.375% Sustainability-Linked Senior Notes due 2030 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL FINANCE NETHERLANDS III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000 4.750% Sustainability-Linked Senior Notes due 2027 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000 5.125% Sustainability-Linked Senior Notes due 2029 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Payment of principal and interest unconditionally guaranteed by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TEVA PHARMACEUTICAL INDUSTRIES LIMITED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>UNDERWRITING AGREEMENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;2, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan AG </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities Europe SA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Euro Representatives (as defined herein) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BofA
Securities Europe SA </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">51 rue La Bo&eacute;tie </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">75008 Paris
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">France </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BNP Paribas </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16, boulevard des Italiens </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">75009 Paris </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">France </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o HSBC Bank plc </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8 Canada Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London E14 5HQ </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan AG </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taunustor 1 (TaunusTurm) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">60310 Frankfurt am Main </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Germany </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: the other Euro Underwriters (as defined herein) listed in Part A of Schedule I hereto </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas Securities Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan AG </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Dollar Representatives (as defined herein) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BofA
Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Bryant Park </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o BNP Paribas Securities Corp. 787 Seventh Avenue
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">USA </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o HSBC Bank plc </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8 Canada Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London E14 5HQ </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan AG </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taunustor 1 (TaunusTurm) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">60310 Frankfurt am Main </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Germany </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To: the other Dollar Underwriters (as defined herein) listed in Part B of Schedule I hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical
Finance Netherlands II B.V. (the &#147;<U>Euro Notes Issuer</U>&#148;), a private company with limited liability (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) organized under the laws of the Netherlands and an indirect wholly-owned
subsidiary of Teva Pharmaceutical Industries Limited, a company organized under the laws of Israel (the &#147;<U>Guarantor</U>&#148;), proposes, subject to the terms and conditions stated herein, to issue and sell 1,100,000,000 in aggregate
principal amount of its 3.750% Sustainability-Linked Senior Notes due 2027 (the &#147;<U>2027 Euro Notes</U>&#148;) and 1,500,000,000 in aggregate principal amount of its 4.375% Sustainability-Linked Senior Notes due 2030 (the &#147;<U>2030 Euro
Notes</U>&#148; and, together with the 2027 Euro Notes, the &#147;<U>Euro Notes</U>&#148;), which Euro Notes are to be guaranteed by the Guarantor (the &#147;<U>Euro Guarantees</U>&#148; and, together with the Euro Notes, the &#147;<U>Euro
Securities</U>&#148;), to the underwriters named in Part A of Schedule I hereto (individually, each a &#147;<U>Euro Underwriter</U>&#148; and, collectively, the &#147;<U>Euro Underwriters</U>&#148;), for whom BofA Securities Europe SA, BNP Paribas,
HSBC Bank plc and J.P. Morgan AG are acting as representatives (the &#147;<U>Euro Representatives</U>&#148;). Teva Pharmaceutical Finance Netherlands III B.V. (the &#147;<U>Dollar Notes Issuer</U>&#148; and, together with the Euro Notes Issuer, the
&#147;<U>Issuers</U>&#148;), a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) organized under the laws of the Netherlands and an indirect wholly-owned subsidiary of the Guarantor, proposes, subject to
the terms and conditions stated herein, to issue and sell $1,000,000,000 in aggregate principal amount of its 4.750% Sustainability-Linked Senior Notes due 2027 (the &#147;<U>2027 Dollar Notes</U>&#148;) and $1,000,000,000 in aggregate principal
amount of its 5.125% Sustainability-Linked Senior Notes due 2029 (the &#147;<U>2029 Dollar Notes</U>&#148; and, together with the 2027 Dollar Notes, the &#147;<U>Dollar Notes</U>&#148; and, together with the Euro Notes, the
&#147;<U>Notes</U>&#148;), which Dollar Notes are to be guaranteed by the Guarantor (the &#147;<U>Dollar Guarantees</U>&#148; and, together with the Dollar Notes, the &#147;<U>Dollar Securities</U>&#148; and, the Dollar Guarantees together with the
Euro Guarantees, the &#147;<U>Guarantees</U>&#148; and, the Dollar Securities together with the Euro Securities, the &#147;<U>Securities</U>&#148;), to the underwriters named in Part B of Schedule I hereto (individually, each a &#147;<U>Dollar
Underwriter</U>&#148; and collectively, the &#147;<U>Dollar Underwriters</U>&#148; and, together with the Euro Underwriters, the &#147;<U>Underwriters</U>&#148; and each individually an &#147;<U>Underwriter</U>&#148;), for whom BofA Securities,
Inc., BNP Paribas Securities Corp., HSBC Bank plc and J.P. Morgan AG are acting as representatives (the &#147;<U>Dollar Representatives</U>&#148; and, together with the Euro Representatives, the &#147;<U>Representatives</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Euro Securities will be issued pursuant to an indenture, dated as of March&nbsp;14, 2018
(such indenture, the &#147;<U>Existing Euro Notes Indenture</U>&#148;), to be supplemented by a third supplemental indenture to be dated as of the Delivery Date (the &#147;<U>Supplemental Euro Notes Indenture</U>&#148;), among the Euro Notes Issuer,
the Guarantor, The Bank of New York Mellon, as trustee (the &#147;<U>Trustee</U>&#148;) and The Bank of New York Mellon, London Branch, as principal paying agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Dollar Securities will be issued pursuant to an indenture, dated as of March&nbsp;14, 2018 (such indenture, the &#147;<U>Existing Dollar
Notes Indenture</U>&#148; and, together with the Existing Euro Notes Indenture, the &#147;<U>Existing Indentures</U>&#148;), to be supplemented by a third supplemental indenture to be dated as of the Delivery Date (as defined in Section&nbsp;2(a))
(the &#147;<U>Supplemental Dollar Notes Indenture</U>&#148; and, together with the Supplemental Euro Notes Indenture, the &#147;<U>Supplemental Indentures</U>&#148; and, the Supplemental Indentures together with the Existing Indentures, the
&#147;<U>Indentures</U>&#148; and each individually an &#147;<U>Indenture</U>&#148;), among the Dollar Notes Issuer, the Guarantor and the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Underwriters have advised the Issuers and the Guarantor that they will offer and sell the Securities purchased from the Issuers and the
Guarantor hereunder in accordance with Section&nbsp;2 of this Agreement as soon as they deem advisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This Agreement, the Indentures
and the Notes are referred to herein collectively as the &#147;<U>Operative Documents</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any reference herein to the Registration
Statement, the Prospectus and the Preliminary Prospectus shall be deemed to refer to and include the Incorporated Documents as of the Effective Time of the Registration Statement or the issue date of such Prospectus or Preliminary Prospectus,
respectively, and any reference herein to the terms &#147;amend,&#148; &#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, the Prospectus and the Preliminary Prospectus shall be deemed to refer to and include
the filing of any document under the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), after the Effective Time of the Registration Statement or the issue date of the Prospectus or Preliminary Prospectus,
respectively, deemed to be incorporated therein by reference. Certain capitalized terms used herein are defined in Section&nbsp;19. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This
is to confirm the agreement between the Issuers, the Guarantor and the Underwriters concerning the issue, offer and sale of the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <I>Representations, Warranties and Agreements of the Issuers and the Guarantor</I>. Each of the Issuers (except for the representation in
Section&nbsp;1(ll), which is given by the Euro Notes Issuer only) and the Guarantor, jointly and severally, represent, warrant to and agree with, the Underwriters that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) The Registration Statement, setting forth information with respect to the Issuers, the Guarantor and the Securities is an
automatic shelf registration statement as defined in Rule 405 of the rules and regulations of the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act (the &#147;<U>Rules and Regulations</U>&#148;). The
Registration Statement, including the Base prospectus, has (i)&nbsp;been prepared by the Issuers and the Guarantor in conformity in all material respects with the requirements of the Securities Act of 1933, as amended (the &#147;<U>Securities
Act</U>&#148;), (ii) been filed with the Commission under the Securities Act and (iii)&nbsp;become effective upon filing under the Securities Act. The Issuers and the Guarantor have included in such registration statement, as amended at the
Effective Time, all information required by the Securities Act and the rules thereunder to be included in such registration statement and the Base prospectus. The Issuers may have filed with the Commission a Preliminary Prospectus pursuant to Rule
424(b) of the Rules and Regulations, which has previously been furnished to the Underwriters. The Issuers and the Guarantor will file with the Commission the Prospectus in accordance with Rule 424(b) of the Rules and Regulations. As filed, such
Prospectus will contain all information required by the Securities Act and the Rules and Regulations, and, except to the extent the Representatives will agree in writing to a modification, will be in all substantial respects in the form furnished to
the Underwriters prior to the Execution Time, or, to the extent not completed at the Execution Time, shall contain only such additional information and other changes as the Issuers and Guarantor have advised the Underwriters, prior to the Execution
Time, will be included or made therein or such changes as are made after consulting with the Underwriters or their counsel. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) The conditions for use of Form <FONT STYLE="white-space:nowrap">S-3,</FONT> as set forth in the General Instructions
thereto, have been satisfied or waived. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c) The Registration Statement conforms, and the Prospectus and any
further amendments or supplements to the Registration Statement or the Prospectus will, when they are filed with the Commission, conform in all material respects to the requirements of the Securities Act and the Trust Indenture Act of 1939, as
amended (the &#147;<U>Trust Indenture Act</U>&#148;). The Registration Statement and any amendment thereto did not, as of the Effective Time and at the Execution Time, contain any untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. The Prospectus does not and will not, as of the date thereof and on the Delivery Date,
contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, it being
understood that none of the Issuers or the Guarantor makes any representation or warranty as to (i)&nbsp;information contained in or omitted from the Registration Statement or the Prospectus in reliance upon and in conformity with written
information furnished to the Issuers and the Guarantor by the Representatives, on behalf of the Underwriters, specifically for inclusion therein as provided in Section&nbsp;7(e) and (ii)&nbsp;that part of the Registration Statement that constitutes
the Statement of Eligibility and Qualification (Form <FONT STYLE="white-space:nowrap">T-1)</FONT> of the Trustee under the Trust Indenture Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d) The Incorporated Documents as amended or supplemented at the date hereof, when they were filed with the Commission,
conformed in all material respects to the requirements of the Securities Act and the Exchange Act. None of the Incorporated Documents as amended or supplemented at the date hereof, when such documents were filed with the Commission, contained any
untrue statement of a material fact or omitted to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. Any further
documents so filed and incorporated by reference in the Prospectus, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e) (i) The Disclosure Package,<B> </B>when taken together as a whole, and (ii)&nbsp;each electronic road show, when taken
together as a whole with the Disclosure Package, as of the Execution Time, do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The preceding sentence does not apply to information contained in or omitted from the Disclosure Package or in any electronic road show in reliance upon and in conformity with written information furnished
to the Issuers and the Guarantor by the Representatives, on behalf of the Underwriters, specifically for inclusion therein as provided in Section&nbsp;7(e). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f) (i) At the time of filing the Registration Statement, (ii)&nbsp;at the
time of the most recent amendment thereto, if any, for the purposes of complying with Section&nbsp;10(a)(3) of the Securities Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Sections 13 or 15(d) of
the Exchange Act or form of prospectus), (iii) at the time the Issuers and the Guarantor or any person acting on their behalf (within the meaning, for this clause only, of Rule 163(c) of the Rules and Regulations) made any offer relating to the
Securities in reliance on the exemption in Rule 163 of the Rules and Regulations, and (iv)&nbsp;at the Execution Time (with such date being used as the determination date for purposes of this clause (iv)), the Guarantor was or is (as the case may
be) a &#147;well-known seasoned issuer&#148; as defined in Rule 405 of the Rules and Regulations. The Issuers and the Guarantor agree to pay the fees required by the Commission relating to the Securities within the time required by Rule 456(b)(1) of
the Rules and Regulations without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) of the Rules and Regulations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g) (i) At the earliest time after the filing of the Registration Statement that the Issuers or the Guarantor or another
offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Rules and Regulations) of the Securities and (ii)&nbsp;as of the Execution Time (with such date being used as the determination date for purposes of this clause
(ii)), the Issuers and the Guarantor were not and are not Ineligible Issuers (as defined in Rule 405 of the Rules and Regulations), without taking account of any determination by the Commission pursuant to Rule 405 of the Rules and Regulations that
it is not necessary that either the Issuers or the Guarantor be considered an Ineligible Issuer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h) Each Issuer Free
Writing Prospectus and the final term sheet prepared and filed pursuant to Section&nbsp;3(c) hereto do not include any information that conflicts with the information contained in the Registration Statement, including the Incorporated Documents and
the Preliminary Prospectus and the Prospectus deemed to be a part thereof that has not been superseded or modified. The preceding sentence does not apply to information contained in or omitted from the Disclosure Package in reliance upon and in
conformity with written information furnished to the Issuers and the Guarantor by the Representatives, on behalf of the Underwriters, specifically for inclusion therein as provided in Section&nbsp;7(e). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Each of the Issuers and the Guarantor have not engaged in any form of solicitation, advertising or other action
constituting an offer or a sale under the Israeli Securities Law 5728-1968, as amended (the &#147;<U>Israeli Securities Law</U>&#148;), and the regulations promulgated thereunder in connection with the offer and sale of the Securities contemplated
hereby, other than offering Securities solely to qualified investors of the type listed on the First Addendum to the Israeli Securities Law, and, assuming the Underwriters&#146; compliance with Section&nbsp;6(f) hereof, are not required to publish a
prospectus in Israel with respect to the offer and sale of the Securities contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(j) Each of the Guarantor
and each &#147;significant subsidiary&#148; of the Guarantor (as such term is defined in Rule <FONT STYLE="white-space:nowrap">1-02(w)</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X)</FONT> (each, a &#147;<U>Significant
Subsidiary</U>&#148; and, collectively, the &#147;<U>Significant Subsidiaries</U>&#148;) has been duly organized and is validly existing in good standing (in all jurisdictions in which such concept is relevant) under the laws of the jurisdiction in
which it is chartered or organized, is duly qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which its ownership or lease of property or the conduct of its business requires such qualification (except
for where the failure to be so qualified would not have a material adverse effect on the business, properties, financial condition, results of operations or prospects of the Guarantor and its subsidiaries, taken as a whole, except as set forth in or
contemplated in each of the Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto) (a &#147;<U>Material Adverse Effect</U>&#148;)), and has all corporate power and authority necessary to own or hold its properties
and to conduct its business as described in each of the Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(k) Each of the Issuers
has been duly organized and is validly existing as a private company with limited liability (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) under the laws of the Netherlands, is qualified to do business and is in good standing as a
foreign corporation in each jurisdiction in which its ownership or lease of property or the conduct of its businesses requires such qualification (except for where the failure to be so qualified would not have a Material Adverse Effect), and has all
corporate power and authority necessary to own or hold its properties and to conduct its businesses as described in each of the Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(l) All of the outstanding shares of capital stock of each Significant Subsidiary of the Guarantor have been duly and validly
authorized and issued and are fully paid and nonassessable, and, except as otherwise set forth in each of the Disclosure Package and the Prospectus, all outstanding shares of capital stock of such subsidiaries are owned by the Guarantor either
directly or through wholly-owned subsidiaries free and clear of any perfected security interest or any other security interests, claims, liens or encumbrances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(m) All of the outstanding shares of capital stock of each of the Issuers
have been duly authorized and validly issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and were not issued in violation of any preemptive or similar rights granted pursuant to the organizational documents of each of
the Issuers or any statutory provisions of Dutch law, and all outstanding shares of each of the Issuers are owned by the Guarantor either directly or through wholly-owned subsidiaries free and clear of any perfected security interest or any other
security interests, claims, liens or encumbrances. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(n) The Guarantor has an authorized capitalization as set forth in
each of the Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(o) The statements contained in each of the Preliminary Prospectus
under the caption &#147;Description of the Euro Notes and the Guarantees&#148; and &#147;Description of the USD Notes and the Guarantees,&#148; as supplemented by the final term sheet prepared and filed pursuant to Section&nbsp;3(c) hereof, insofar
as they purport to summarize the provisions of the Indentures and the Securities, are accurate and complete in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(p) Neither the execution, delivery and performance of this Agreement and the other Operative Documents by the applicable
Issuer and the Guarantor, nor the issuance of the Securities under this Agreement will (x)&nbsp;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, any indenture, mortgage, deed of
trust, loan agreement or other agreement or instrument to which such Issuer or the Guarantor is a party or by which such Issuer or the Guarantor is bound or to which any of the properties or assets of such Issuer or the Guarantor is subject, except
for any conflict, breach or violation that would not have, individually or in the aggregate, a Material Adverse Effect, (y)&nbsp;result in any violation of the provisions of the memorandum of association or the articles of association of the
Guarantor or the organizational documents of such Issuer or (z)&nbsp;result in any violation in any material respect of any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the applicable
Issuer or the Guarantor or any of their respective properties or assets; and except (i)&nbsp;such as have been or will be obtained under the Securities Act, the Trust Indenture Act and the rules and regulations promulgated thereunder, (ii)&nbsp;as
may be required by the securities or &#147;blue sky&#148; laws of any state of the United States, (iii)&nbsp;as may be required under the applicable laws of the Netherlands, (iv)&nbsp;for the filing or furnishing of public announcements in
connection with the issue and offer of the Securities with the Commission, the New York Stock Exchange, the Israel Securities Authority, the Tel Aviv Stock Exchange and the Israeli Companies Registrar that may be required to be made on or after the
date of this Agreement and the Closing Date, as applicable, and (v)&nbsp;with respect to the Euro Notes only, as may be required under the rules and regulations of the Euronext Dublin with respect to the listing thereon of the Euro Notes, no
consent, approval, authorization or order of, or filing or registration with, any such court or governmental agency or body is required for the execution, delivery and performance of the Operative Documents by each of the Issuers and the Guarantor,
and the consummation of the offer and sale of the Securities contemplated hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(q) Each of the Issuers and the Guarantor has all necessary corporate
right, power and authority to execute and deliver this Agreement and perform its obligations hereunder; and this Agreement, and the offer and sale of the Securities contemplated hereby, have been duly authorized, and this Agreement has been duly
executed and delivered by each of the Issuers and the Guarantor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(r) Each of the Issuers and the Guarantor has all
necessary corporate right, power and authority to execute and deliver each of the Supplemental Indentures to which it is party and perform its obligations thereunder; each of the Supplemental Indentures has been duly authorized by the Issuer party
thereto and the Guarantor, and on the Delivery Date, each of the Supplemental Indentures which will be qualified under the Trust Indenture Act and will have been duly executed and delivered by the Issuer party thereto and the Guarantor and, assuming
due authorization, execution and delivery of each of the Supplemental Indentures by the Trustee and (in the case of the Supplemental Euro Notes Indenture) the principal paying agent party thereto, will constitute a legally valid and binding
agreement of each of the Issuers party thereto and the Guarantor, enforceable against each of the Issuers party thereto and the Guarantor in accordance with its terms, except as the enforceability thereof may be limited by bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and other similar laws relating to or affecting creditors&#146; rights generally, subject to general principles of equity and to limitations on availability of equitable relief, including specific
performance (whether considered in a proceeding in equity or at law) and an implied covenant of good faith and fair dealing (collectively, the &#147;<U>Enforceability Exceptions</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(s) Each of the Existing Indentures has been duly authorized, executed and delivered by the Issuer party thereto and the
Guarantor, and, assuming due authorization, execution and delivery of each of the Existing Indentures by the Trustee and (in the case of the Existing Euro Notes Indenture) the principal paying agent party thereto, constitutes a legally valid and
binding agreement of each of the Issuers party thereto and the Guarantor, enforceable against each of the Issuers party thereto and the Guarantor in accordance with its terms, except as the enforceability thereof may be limited by the Enforceability
Exceptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(t) Each of the Issuers and the Guarantor has all necessary corporate
right, power and authority to execute, issue and deliver the Notes and Guarantees, respectively, and perform its obligations thereunder; the Notes have been duly authorized by each of the applicable Issuers and the Guarantees have been duly
authorized by the Guarantor; when the Notes are executed, authenticated and issued in accordance with the terms of the applicable Indenture and delivered to and paid for by the Underwriters pursuant to this Agreement on the Delivery Date (assuming
due authentication of the Notes by the Trustee), such Notes will constitute legally valid and binding obligations of each of the applicable Issuers, entitled to the benefits of the applicable Indenture and enforceable against each of the applicable
Issuers in accordance with their terms, except as the enforceability thereof may be limited by the Enforceability Exceptions; when the Guarantees are executed and issued in accordance with the terms of the applicable Indenture and the Notes on which
they are endorsed have been executed in accordance with the applicable Indenture and delivered to and paid for by the Underwriters pursuant to this Agreement on the Delivery Date, such Guarantees will constitute legally valid and binding obligations
of the Guarantor, and enforceable against the Guarantor in accordance with their terms, except as the enforceability thereof may be limited by the Enforceability Exceptions, and entitled to the benefit of the applicable Indenture. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(u) Except as described in each of the Disclosure Package and the Prospectus, there are no contracts, agreements or
understandings between each of the Issuers or the Guarantor and any person granting such person the right (other than rights which have been waived or satisfied) to require the Issuers or the Guarantor to file a registration statement under the
Securities Act with respect to any securities of the Issuers or the Guarantor owned or to be owned by such person or to require the Issuers or the Guarantor to include such securities in any securities being registered pursuant to any registration
statement filed by the Issuers or the Guarantor under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) Except as would not have a Material
Adverse Effect, (x)&nbsp;the Guarantor, since the date of the latest audited financial statements incorporated by reference in the Disclosure Package, and (y)&nbsp;each of the Issuers, at any time since its respective formation, has not sustained
any loss or interference with its respective business from fire, explosion, flood or other calamity, whether or not covered by insurance, or, except as described in each of the Disclosure Package and the Prospectus, from any labor dispute or court
or governmental action, order or decree; and (i)&nbsp;with respect to each of the Issuers, since the respective date on which it became a wholly-owned subsidiary of the Guarantor, and (ii)&nbsp;with respect to the Guarantor, since the date of the
most recent audited financial statements incorporated by reference in the Disclosure Package, except for the transactions contemplated hereby or as described in each of the Disclosure Package and the Prospectus, there has not been any change in such
entity&#146;s respective capital stock or long-term debt of each of the Issuers or the Guarantor, or any change or any development including a prospective change that would have a Material Adverse Effect, except for any grants under the employee
stock plans of the Guarantor or its subsidiaries (the &#147;<U>Authorized Grants</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(w) The consolidated financial statements of the Guarantor (including the
related notes and supporting schedules) incorporated by reference in the Disclosure Package present fairly, in all material respects, the financial condition and results of operations of the Guarantor and its consolidated subsidiaries at the dates
and for the periods indicated, comply as to form in all material respects with the applicable accounting requirements of the Securities Act and the Rules and Regulations and have been prepared in conformity with generally accepted accounting
principles in the United States applied on a consistent basis throughout the periods involved, subject to, only in the case of the unaudited financial statements, ordinary <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) Kesselman&nbsp;&amp; Kesselman, who audited the annual financial statements of the Guarantor, incorporated by reference
in each of the Disclosure Package and the Prospectus, and whose report is incorporated by reference therein, is the independent registered accounting firm with respect to the Guarantor within the meaning of the Securities Act and the Rules and
Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(y) Except as would not have a Material Adverse Effect and except as disclosed in each of the Disclosure
Package and the Prospectus, the Guarantor and its subsidiaries own or possess, or hold valid licenses in respect of, all patents, patent rights, licenses, inventions, copyrights, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets,
trademarks, service marks and trade names necessary for the conduct of their respective businesses in the manner described in each of the Disclosure Package and the Prospectus, and, except as described in each of the Disclosure Package and the
Prospectus, the Guarantor has not received any notice of, and has no knowledge of, any infringement of or conflict with asserted rights of others with respect to any of the foregoing which, singly or in the aggregate, would be reasonably likely to
have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(z) Each of the Issuers and the Guarantor possesses all certificates, authorizations and
permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct its business as now conducted and as described in each of the Disclosure Package and the Prospectus, except for such certificate, authorizations
and permits the failure of which to possess, singly or in the aggregate, would not have a Material Adverse Effect, and neither the Issuers nor the Guarantor have received any notice of proceedings relating to the revocation or modification of any
such certificate, authorization or permit, which singly or in the aggregate, would be reasonably likely to have a Material Adverse Effect, except as described in each of the Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(aa) Except as disclosed in each of the Disclosure Package and the
Prospectus, there are no legal or governmental proceedings pending to which either of the Issuers or the Guarantor or any subsidiary of the Guarantor is a party or of which any property or asset of the Issuers or the Guarantor is the subject which,
singly or in the aggregate, would be reasonably likely to have a Material Adverse Effect; and to the knowledge of each of the Issuers and the Guarantor, no such proceedings are threatened or contemplated by governmental authorities or, except as set
forth or contemplated in each of the Disclosure Package and the Prospectus, threatened by others. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(bb) Each of the
Issuers and the Guarantor is not (i)&nbsp;in violation of its organizational documents, (ii)&nbsp;in default and no event has occurred which, with notice or lapse of time or both, would constitute such a default, in the due performance or observance
of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its properties or assets is subject or
(iii)&nbsp;in violation of any law, ordinance, governmental rule, regulation or court decree to which it or its properties or assets may be subject or has failed to obtain any license, permit, certificate, franchise or other governmental
authorization or permit necessary to the ownership of its properties or to the conduct of its business, except to the extent that any such default, event or violation described in the foregoing clauses (ii)&nbsp;and (iii) would not have a Material
Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(cc) The Guarantor is subject to and in compliance in all material respects with the reporting
requirements of Sections 13 and 15(d) of the Exchange Act and the rules and regulations promulgated under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(dd) The Guarantor and its subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and
local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (&#147;<U>Environmental Laws</U>&#148;), (ii) have received all permits,
licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval, except in each case of
clauses (i), (ii) and (iii)&nbsp;where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not,
singly or in the aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ee) Each of the Guarantor and its subsidiaries, in its reasonable
judgment, has concluded that there are no costs or liabilities associated with its respective compliance with Environmental Laws (including, without limitation, any capital or operating expenditures required for
<FONT STYLE="white-space:nowrap">clean-up,</FONT> closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which
would, singly or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ff) There are no stamp or other issuance or transfer
taxes or duties or other similar fees or charges required to be paid, under Israeli or U.S. federal law or the laws of any U.S. state, by or on behalf of the Underwriters in connection with (A)&nbsp;the issuance, sale and delivery of the Securities
to be sold by the Issuers in the manner contemplated by this Agreement, (B)&nbsp;the sale and delivery by the Underwriters of the Securities as contemplated herein or (C)&nbsp;the execution and delivery of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(gg) Each of the Issuers and the Guarantor has filed all foreign, national, federal, state and local tax returns that are
required to be filed or has requested extensions thereof (except in any case in which the failure so to file would not have a Material Adverse Effect) and has paid (or withheld) all taxes required to be paid (or withheld) by it and any other
assessment, fine or penalty levied against it, to the extent that any of the foregoing is due and payable, except for any such assessment, fine or penalty that is currently being contested in good faith or as would not have a Material Adverse
Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(hh) No subsidiary of the Guarantor (other than each of the Issuers) is currently prohibited, directly or
indirectly, from paying any dividends to the Guarantor, from making any other distribution on such subsidiary&#146;s capital stock, from repaying to the Guarantor any loans or advances to such subsidiary from the Guarantor or from transferring any
of such subsidiary&#146;s property or assets to the Guarantor or any other subsidiary of the Guarantor, except as described in or contemplated by each of the Disclosure Package and the Prospectus or except as would not have a Material Adverse
Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) Each of the Issuers and the Guarantor, as of the date hereof and the
Closing Date, maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorizations; (ii)&nbsp;transactions are
recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#146;s
general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(jj) Neither of the Issuers nor the Guarantor is an &#147;investment company&#148; or an entity &#147;controlled&#148; by an
&#147;investment company&#148; within the meaning of such term under the Investment Company Act of 1940, as amended (the &#147;<U>Investment Company Act</U>&#148;), and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(kk) Except as disclosed in the Disclosure Package or the Prospectus, payments of interest in respect of the Securities held
by <FONT STYLE="white-space:nowrap">non-Israeli</FONT> residents are not subject to withholding or deduction for or on account of any taxes, duties or other charges of whatever nature imposed by Israel or any authority thereof or therein having the
power to tax. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ll) Application has been made to admit the Euro Notes to the Official List of Euronext Dublin and trading
on the Global Exchange Market and, in connection therewith, the Euro Notes Issuer has caused to be prepared and submitted to Euronext Dublin a listing application with respect to the Euro Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(mm) Neither the Guarantor nor any of its subsidiaries nor, to the
knowledge of the Guarantor, any director, officer, agent, employee or affiliate of the Guarantor or any of its subsidiaries is a person or entity with whom dealings are restricted or prohibited pursuant to any sanctions administered by the United
States (including the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S. Department of State or the U.S. Department of Commerce) or any sanctions imposed by the United Nations Security Council, the European Union, Her
Majesty&#146;s Treasury of the United Kingdom or other relevant sanctions authority, excluding the Arab League (collectively, the &#147;<U>Sanctions</U>&#148; and each such person or entity, a &#147;<U>Sanctioned Person</U>&#148;), nor is the
Guarantor or any of its subsidiaries organized under the laws of or ordinarily resident in a country or territory that is the subject of Sanctions that broadly prohibit dealings with that country or territory (which currently comprise Cuba, Iran,
Syria, North Korea and Crimea) (each, a &#147;<U>Sanctioned Country</U>&#148;); and neither of the Issuers nor the Guarantor will directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise
make available such proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of financing the activities of or business with any Sanctioned Person or Sanctioned Country. Further, it is acknowledged and agreed that
this representation given pursuant to this Section&nbsp;1(mm) is sought and given if and to the extent that to do so would not result in any violation or breach of any provision of (and in no case may be construed as requiring any party to this
Agreement to act in violation or breach of)&nbsp;(i) Council Regulation (EC) No 2271/96 of 22&nbsp;November 1996 (or any law or regulation implementing such Regulation in any member state of the European Union), or (ii)&nbsp;Council Regulation (EC)
2271/96 as it forms part of domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (&#147;<U>EUWA</U>&#148;) and/or any similar anti-boycott law in the United Kingdom. The representation and undertakings in this
Section&nbsp;1(mm) are only sought by and given to any Underwriter incorporated in or organized under the laws of the Federal Republic of Germany to the extent that to do so would not result in a violation of or a conflict with the German Foreign
Trade Regulation (<I>Au</I><I>&szlig;</I><I>enwirtschaftsverordnung</I>) and/or any similar anti-boycott law in Germany. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(nn) Neither the Guarantor nor any of its subsidiaries nor, to the knowledge of the Guarantor, any director, officer, agent,
employee or other person associated with or acting on behalf of the Guarantor or any of its subsidiaries, is (i)&nbsp;a person or entity that is organized under the laws of or ordinarily resident in Iran or North Korea, the two jurisdictions
identified by the Financial Action Task Force (&#147;<U>FATF</U>&#148;) in its February 2019 Public Statement as subject to a FATF call on its members and other jurisdictions (a)&nbsp;to apply enhanced due diligence measures proportionate to the
risks arising from the jurisdiction(s), and/or (b)&nbsp;to apply counter-measures to protect the international financial system from the ongoing and substantial money laundering and financing of terrorism risks emanating from the jurisdiction(s),
(each a &#147;<U>FATF Public Statement Jurisdiction</U>&#148;); or (ii)&nbsp;an entity controlled or majority owned by a person or entity organized under the laws of or ordinarily resident in a FATF Public Statement Jurisdiction. The Guarantor will
not directly or indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity to fund any activities or
business of or with: (i)&nbsp;a FATF Public Statement Jurisdiction, (ii)&nbsp;any person or entity organized under the laws of or ordinarily resident in a FATF Public Statement Jurisdiction, or (iii)&nbsp;any entity controlled or majority owned by a
person or entity organized under the laws of or ordinarily resident in a FATF Public Statement Jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(oo) Except as disclosed in the Guarantor&#146;s consolidated financial
statements included in the Disclosure Package and the Prospectus, neither the Guarantor nor any of its subsidiaries nor, to the knowledge of the Guarantor, any director, officer, agent, employee or affiliate of the Guarantor or any of its
subsidiaries has taken any action, directly or indirectly, that would result in a violation by such persons of the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;<U>FCPA</U>&#148;), the
U.K. Bribery Act 2010, or any other anti-corruption or anti-bribery law or regulation of any other jurisdiction to the extent such other laws or regulations are applicable; and the Guarantor, its subsidiaries and, to the knowledge of the Guarantor,
its affiliates have instituted and maintain policies and procedures reasonably designed to promote and achieve compliance with the FCPA, the U.K. Bribery Act 2010 and any other anti-corruption or anti-bribery law or regulation of any other
jurisdiction to the extent applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(pp) The operations of each of the Guarantor and its subsidiaries are and have
been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements, including those of the U.S. Currency and Foreign Transactions Reporting Act of 1970, the UK Money Laundering
Regulations 2007, as amended, as well as all applicable money laundering statutes of all jurisdictions where each of the Guarantor and its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines issued, administered or enforced by any governmental or regulatory agency (collectively, &#147;<U>Anti-Money Laundering Laws</U>&#148;) and no action, suit or proceeding by or before any court or governmental or regulatory
agency, authority or body or any arbitrator involving the Guarantor or any of its subsidiaries with respect to Anti-Money Laundering Laws is pending or, to the best of the Guarantor&#146;s knowledge, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(qq) None of the Guarantor or any of its affiliates has taken, directly or indirectly, any action designed to cause or result
in, or which has constituted or which might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Issuers in connection with the offering of the Securities </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(rr) To the extent that information is required to be publicly disclosed under&#151;Regulation (EU) No 596/2014 on market
abuse and any applicable delegated regulations thereunder, including, without limitation, Commission Delegated Regulation of 8&nbsp;March 2016 supplementing Regulation (EU) 596/2014 with regard to regulatory technical standards for the conditions
applicable to <FONT STYLE="white-space:nowrap">buy-back</FONT> programmes and stabilisation measures (the &#147;Stabilising Rules&#148;) before stabilising transactions can be undertaken in compliance with the safe harbor provided under such
Stabilising Rules, such information has been adequately publicly disclosed (within the meaning of the Stabilising Rules). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ss) The interactive data in the eXtensible Business Reporting Language
(&#147;<U>XBRL</U>&#148;) included or incorporated by reference to the Registration Statement, fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines
applicable thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <I>Purchase, Sale and Delivery of Securities</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Subject to the terms and conditions and in reliance upon the representations and warranties herein set forth, (x)&nbsp;the
Euro Notes Issuer agrees (and the Guarantor agrees to cause the Euro Notes Issuer) to issue and sell to each Euro Underwriter, and each Euro Underwriter agrees, severally and not jointly, to purchase from the Euro Notes Issuer (i)&nbsp;at a purchase
price of 99.450% of the principal amount thereof, the respective principal amount of the 2027 Euro Notes and (ii)&nbsp;at a purchase price of 99.450% of the principal amount thereof, the respective principal amount of the 2030 Euro Notes, in each
case such principal amount Euro Notes as set forth opposite such Euro Underwriter&#146;s name in Part A of Schedule I hereto, and (y)&nbsp;the Dollar Notes Issuer agrees (and the Guarantor agrees to cause the Dollar Notes Issuer) to issue and sell
to each Dollar Underwriter, and each Dollar Underwriter agrees, severally and not jointly, to purchase from the Dollar Notes Issuer (i)&nbsp;at a purchase price of 99.450% of the principal amount thereof, the respective principal amount of the 2027
Dollar Notes and (ii)&nbsp;at a purchase price of 99.450% of the principal amount thereof, the respective principal amount of the 2029 Dollar Notes, in each case such principal amount of Dollar Notes as set forth opposite such Dollar
Underwriter&#146;s name in Part B of Schedule I hereto. The aggregate amount due to the Euro Notes Issuer from the sale of the Euro Notes is hereinafter referred to as the &#147;<U>euro purchase price</U>,&#148; and the aggregate amount due to the
Dollar Notes Issuer from the sale of the Dollar Notes is hereinafter referred to as the &#147;<U>dollar purchase price</U>.&#148; Reference is hereby made to that certain dealer manager agreement dated October&nbsp;27, 2021 between certain of the
Representatives (and/or their affiliates) and the Guarantor pursuant to which the Guarantor has agreed to pay the dealer managers thereunder a fee of $2 for each $1,000, or &#128;2 for each &#128;1,000, as applicable, in principal amount of notes
acquired pursuant to the tender offer referenced therein (the &#147;<U>Tender Fee</U>&#148;). The Representatives severally agree to distribute the Tender Fee (net of any expenses or other costs) on a <I>pro rata</I> basis among the Underwriters in
proportion of the total aggregate principal amount of Securities set opposite the name of each Underwriter in Schedule I hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Delivery of and payment for the Euro Securities shall be made at 9:00 a.m. (London time) on
November&nbsp;9, 2021 and delivery of and payment for the Dollar Securities shall be made at 9:00 a.m. (New York time) on November&nbsp;9, 2021, or such later date as the Representatives shall designate (the &#147;<U>Closing Date</U>&#148;), which
date and time may be postponed by agreement among the Representatives, the Guarantor and each of the Issuers or as provided in Section&nbsp;8 (such date and time of delivery and payment for the Securities being herein called the &#147;<U>Delivery
Date</U>&#148;). Delivery of (i)&nbsp;the Euro Securities shall be made to HSBC Bank plc on behalf of the Euro Underwriters against payment of the euro purchase price by HSBC Bank plc on behalf of the Euro Underwriters, and (ii)&nbsp;the Dollar
Securities shall be made to J.P. Morgan AG on behalf of the Dollar Underwriters against payment of the dollar purchase price by J.P. Morgan AG on behalf of the Dollar Underwriters. Payment for (i)&nbsp;the Euro Securities shall be effected either by
wire transfer of immediately available funds to a bank account, the account details for which are to be provided by the Euro Notes Issuer or the Guarantor to the Euro Representatives at least two business days in advance of the Delivery Date, or by
such other manner of payment as may be agreed by the Euro Notes Issuer or the Guarantor and the Euro Representatives, and (ii)&nbsp;the Dollar Securities shall be effected either by wire transfer of immediately available funds to an account with a
bank in The City of New York, the account number and the ABA number for such bank to be provided by the Dollar Notes Issuer or the Guarantor to the Dollar Representatives at least two business days in advance of the Delivery Date, or by such other
manner of payment as may be agreed by the Dollar Notes Issuer or the Guarantor and the Dollar Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The
Euro Notes Issuer will deliver against payment of the euro purchase price the Euro Securities in the form of one or more permanent global certificates (the &#147;<U>Euro Global Securities</U>&#148;). The Euro Global Securities will be deposited on
the Delivery Date with, and registered in the name of a common depositary for, Euroclear Bank SA/NV (&#147;<U>Euroclear</U>&#148;) and for Clearstream Banking S.A. (&#147;<U>Clearstream</U>&#148;). Beneficial interests in the Euro Securities will be
shown on, and transfers thereof will be effected only through, records maintained in book-entry form by Euroclear or Clearstream, as applicable. The Euro Global Securities will be made available, at the request of the Euro Representatives, for
checking at least 24 hours prior to the Delivery Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Dollar Notes Issuer will deliver against payment of the
dollar purchase price the Dollar Securities in the form of one or more permanent global certificates (the &#147;<U>Dollar Global Securities</U>&#148;), registered in the name of Cede&nbsp;&amp; Co., as nominee for The Depository Trust Company
(&#147;<U>DTC</U>&#148;). Beneficial interests in the Dollar Securities will be shown on, and transfers thereof will be effected only through, records maintained in book-entry form by DTC and its participants, Euroclear or Clearstream, as
applicable. The Dollar Global Securities will be made available, at the request of the Dollar Representatives, for checking at least 24 hours prior to the Delivery Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Time shall be of the essence, and delivery at the time and place specified pursuant to this Agreement is a further
condition of the obligations of the Underwriters hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Solely for the purposes of the requirements of Article 9(8) of the
MIFID Product Governance rules under EU Delegated Directive 2017/593 (the &#147;<U>Product Governance Rules</U>&#148;) regarding the mutual responsibilities of manufacturers under the Product Governance Rules: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) with respect to the Euro Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) BofA Securities Europe SA and J.P. Morgan AG (each a &#147;<U>Euro EU Manufacturer</U>&#148; and together the &#147;<U>Euro EU
Manufacturers</U>&#148;) acknowledges to each other Euro EU Manufacturer that it understands the responsibilities conferred upon it under the Product Governance Rules relating to each of the product approval process, the target market and the
proposed distribution channels as applying to the Euro Securities and the related information set out in the Preliminary Prospectus, the Prospectus. the Registration Statement and any other announcements in connection with the Euro Securities; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) the Euro Notes Issuer and the Guarantor note the application of the Product Governance Rules and acknowledge the target market and
distribution channels identified as applying to the Euro Securities by the Euro EU Manufacturers and the related information set out in the Preliminary Prospectus, the Prospectus, the Registration Statement and any other announcements in connection
with the Euro Securities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) with respect to the Dollar Securities: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) J.P. Morgan AG (the &#147;<U>Dollar EU Manufacturer</U>&#148;) acknowledges to each other Dollar EU Manufacturer that it understands the
responsibilities conferred upon it under the Product Governance Rules relating to each of the product approval process, the target market and the proposed distribution channels as applying to the Dollar Securities and the related information set out
in the Preliminary Prospectus, the Prospectus. the Registration Statement and any other announcements in connection with the Dollar Securities; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) the Dollar Notes Issuer and the Guarantor note the application of the Product Governance Rules and acknowledge the target market and
distribution channels identified as applying to the Dollar Securities by the Dollar EU Manufacturer and the related information set out in the Preliminary Prospectus, the Prospectus, the Registration Statement and any other announcements in
connection with the Dollar Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Solely for the purposes of the requirements of 3.2.7R of the FCA Handbook
Product Intervention and Product Governance Sourcebook (the &#147;<U>UK MiFIR Product Governance Rules</U>&#148;) regarding the mutual responsibilities of manufacturers under the UK MiFIR Product Governance Rules: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) with respect to the Euro Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) HSBC Bank plc and BNP Paribas (each a &#147;<U>UK Euro Manufacturer</U>&#148; and together the &#147;<U>UK Euro Manufacturers</U>&#148;)
acknowledges to each other UK Euro Manufacturers that it understands the responsibilities conferred upon it under the UK MiFIR Product Governance Rules relating to each of the product approval process, the target market and the proposed distribution
channels as applying to the Euro Securities and the related information set out in the announcements in connection with the Euro Securities; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) the Euro Notes Issuer and the Guarantor note the application of the UK MiFIR Product
Governance Rules and acknowledge the target market and distribution channels identified as applying to the Euro Securities by the UK Euro Manufacturers and the related information set out in the announcements in connection with the Euro Securities.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) with respect to the Dollar Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) HSBC Bank plc (the &#147;<U>UK Dollar Manufacturer</U>&#148;) acknowledges to each other UK Dollar Manufacturer that it understands the
responsibilities conferred upon it under the UK MiFIR Product Governance Rules relating to each of the product approval process, the target market and the proposed distribution channels as applying to the Dollar Securities and the related
information set out in the announcements in connection with the Dollar Securities; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) the Dollar Notes Issuer and the Guarantor
note the application of the UK MiFIR Product Governance Rules and acknowledge the target market and distribution channels identified as applying to the Dollar Securities by the UK Dollar Manufacturer and the related information set out in the
announcements in connection with the Dollar Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <I>Further Agreements of the Issuers and the Guarantor</I>. Each of the
Issuers (except for the agreements in Section&nbsp;3(a) and Section&nbsp;3(r), which are given by the Euro Notes Issuer only) and the Guarantor, jointly and severally, further agree: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) (i) To use reasonable efforts to have the Euro Notes admitted to the Official List of Euronext Dublin and admitted to
trading on the Global Exchange Market as soon as reasonably practicable; and (ii)&nbsp;to use reasonable efforts to maintain such listing for as long as any of the Euro Notes are outstanding. If the Euro Notes cease to be listed on the Global
Exchange Market of the Euronext Dublin, the Euro Notes Issuer and the Guarantor shall use reasonable efforts to relist the Euro Notes on the Euronext Dublin or to list the Euro Notes on such other recognized stock exchange promptly and in any event
before the date of the next interest payment on the Euro Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) To prepare the Prospectus in a form approved by the Representatives,
which approval shall not be unreasonably withheld or delayed, and to file such Prospectus pursuant to Rule 424(b) of the Rules and Regulations not later than Commission&#146;s close of business on the second Business Day following the execution and
delivery of this Agreement; (ii)&nbsp;to make no further amendment or any supplement to the Registration Statement or to the Prospectus (including to any Preliminary Prospectus) prior to the Delivery Date except as permitted or required herein;
(iii)&nbsp;to advise the Representatives, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or any supplement to the Prospectus or any amended Prospectus has been filed and to
furnish the Underwriters with copies thereof; (iv)&nbsp;to file promptly all reports required to be filed by the Issuer with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the
Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Securities; (v)&nbsp;to advise the Representatives, promptly after it receives notice thereof, of the issuance by the Commission of
any stop order or of any order preventing or suspending or objecting to the use of the Prospectus, of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding
for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and (vi)&nbsp;in the event of the issuance of any stop order or of any order
preventing or suspending or objecting to the use of the Prospectus or suspending any such qualification, to use promptly its reasonable best efforts to obtain its withdrawal, including, if necessary, by filing an amendment to the Registration
Statement or a new registration statement and using its best efforts to have such amendment or new registration statement declared effective as soon as practicable </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) To prepare a final term sheet, containing solely a description of the Securities and the offering thereof, in a form
approved by the Representatives and to file such term sheet pursuant to Rule 433(d) of the Rules and Regulations within the time required by such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) (i) Each of the Issuers and the Guarantor agrees that, unless it obtains or will obtain the prior written consent of the
Representatives, and (ii)&nbsp;each Underwriter, severally and not jointly, agrees with the Issuers and the Guarantor that, unless it has obtained or will obtain, as the case may be, the prior written consent of the Guarantor, it has not made and
will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#147;free writing prospectus&#148; (as defined in Rule 405 of the Rules and Regulations) required to be
filed by the Issuers or the Guarantor with the Commission or retained by the Issuers or the Guarantor under Rule 433 of the Rules and Regulations, other than the final term sheet prepared and filed pursuant to Section&nbsp;3(c) hereto; provided that
the prior written consent of the parties hereto shall be deemed to have been given in respect of the Free Writing Prospectuses included in Schedule II hereto and any electronic road show. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Any such free writing prospectus consented to by the Representatives or the Issuers and the
Guarantor is hereinafter referred to as a &#147;Permitted Free Writing Prospectus .&#148; The Issuers and the Guarantor agree that (x) they have treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free
Writing Prospectus and (y)&nbsp;they have complied and will comply, as the case may be, with the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Permitted Free Writing Prospectus, including in respect of timely
filing with the Commission, legending and record keeping. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) (d) To furnish promptly to the Underwriters and to counsel
for the Underwriters, Baker McKenzie LLP, if requested a signed or facsimile signed copy of the Registration Statement as originally filed with the Commission, and each amendment thereto filed with the Commission, including all consents and exhibits
filed therewith </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) If, at any time prior to the filing of the Prospectus pursuant to Rule 424(b) of the Rules and
Regulations, any event occurs as a result of which the Disclosure Package would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein in the light of the circumstances under which
they were made at such time not misleading, the Issuers will (i)&nbsp;notify promptly the Representatives so that any use of the Disclosure Package may cease until it is amended or supplemented; (ii)&nbsp;amend or supplement the Disclosure Package
to correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement to the Underwriters in such quantities as the Underwriters may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) To deliver promptly to the Underwriters and counsel for the Underwriters such number of the following documents as the
Underwriters shall reasonably request: (i)&nbsp;conformed copies of the Registration Statement as originally filed with the Commission and each amendment thereto (in each case excluding exhibits) and (ii)&nbsp;the Prospectus and any amended or
supplemented Prospectus and any Preliminary Prospectus, and each Issuer Free Writing Prospectus, and, if the delivery of a prospectus is required at any time after the Execution Time in connection with the offering or sale of the Securities
(including in circumstances where such requirement may be satisfied pursuant to Rule 172 of the Rules and Regulations) and if at such time any events shall have occurred as a result of which the Prospectus as then amended or supplemented would
include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading when such Prospectus is delivered, or,
if, in the opinion of counsel for the Underwriters, for any other reason it shall be necessary to amend or supplement the Prospectus in order to comply with the Securities Act, to notify the Representatives and, upon their request, to prepare and
furnish without charge to the Underwriters and to any dealer in securities as many copies of an amended or supplemented Prospectus which will correct such statement or omission or effect such compliance as the Underwriters may from time to time
reasonably request. The Issuers will pay the expenses of printing and distributing to the Underwriters all such documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) During the time that delivery of a prospectus is required for the
initial offering and sale of Securities (including in circumstances where such requirement may be satisfied pursuant to Rule 172 of the Rules and Regulations), to file promptly with the Commission any amendment to the Registration Statement or the
Prospectus or any supplement to the Prospectus, or new registration statement, that may, in the reasonable judgment of the Issuers or the Representatives, be required by the Securities Act or that is requested by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) For so long as the delivery of a prospectus is required in connection with the initial offering or sale of the Securities
(including in circumstances where such requirement may be satisfied pursuant to Rule 172 of the Rules and Regulations), prior to filing with the Commission any amendment to the Registration Statement, supplement to the Prospectus, Prospectus
(including any Preliminary Prospectus), any document incorporated by reference in the Prospectus or any new registration statement, to furnish a copy thereof to the Underwriters and counsel for the Underwriters and obtain the consent of the
Representatives, which consent shall not unreasonably be withheld or delayed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) [Reserved]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) To apply the proceeds from the sale of the Securities as set forth under &#147;Use of Proceeds&#148; in each of the
Preliminary Prospectus and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) From the date hereof through the Closing Date, not to, directly or
indirectly, offer for sale, sell or otherwise dispose of (or enter into any transaction or device which is designed to, or could be expected to, result in the disposition or purchase by any person at any time in the future of), or announce an
offering of any debt securities issued or guaranteed by the Guarantor or either of the Issuers without the prior written consent of the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Not to take, directly or indirectly, any action designed to cause or result in, or which has constituted or which might
reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Guarantor or either of the Issuers in connection with the offering of the Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Cooperate with the Representatives, if necessary, for the qualification
of the Securities for sale by the Underwriters under the laws of such jurisdictions as the Representatives may designate (including Japan and certain provinces of Canada) and maintain such qualifications in effect so long as required for the sale of
the Securities; provided that in no event shall the Issuers be obligated to qualify to do business in any jurisdiction where it is not now so qualified or to take any action that would subject it to service of process in suits, other than those
arising out of the offering or sale of the Securities, in any jurisdiction where it is not now so subject or to subject itself to taxation in any jurisdiction wherein it would not otherwise be subject to tax but for the requirements of this
paragraph. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) [Reserved]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) To take such steps as shall be necessary to ensure that neither of the Issuers nor the Guarantor shall become an
&#147;investment company&#148; within the meaning of such term under the Investment Company Act and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(q) To make reasonable commercial efforts so that neither of the Issuers will be deemed an Israeli tax resident. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(r) To use its reasonable best efforts to cause the Securities to be accepted for clearance and settlement through the
facilities of DTC, Euroclear or Clearstream, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(s) To hereby confirm the appointment of HSBC Bank plc in its
role as stabilizing manager (the &#147;<U>Euro Stabilizing Manager</U>&#148;) as the central point responsible for adequate public disclosure of information, and handling any request from a competent authority, in accordance with Article 6(5) of
Commission Delegated Regulation (EU) 2016/1052 of 8&nbsp;March 2016 supplementing Regulation (EU) No.&nbsp;596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buyback
programs and stabilization measures. The Euro Stabilizing Manager for its own account may, to the extent permitted by applicable laws and directives, over-allot and effect transactions with a view to supporting the market price of the Euro
Securities at a level higher than that which might otherwise prevail, but in doing so the Euro Stabilizing Manager shall act as principal and not as agent of the Euro Notes Issuer or the Guarantor and any loss resulting from overallotment and
stabilization shall be borne, and any profit arising therefrom shall be beneficially retained, by the Euro Stabilizing Manager. However, there is no assurance that the Euro Stabilizing Manager (or persons acting on behalf of the Euro Stabilizing
Manager) will undertake any stabilization action. Nothing contained in this paragraph shall be construed so as to require the Euro Notes Issuer to issue, or the Guarantor to guarantee, in excess of (i) &#128;1,100,000,000 in aggregate principal
amount of the 2027 Euro Notes or (ii) &#128;1,500,000,000 in aggregate principal amount of the 2030 Euro Notes. Such stabilization, if commenced, may be discontinued at any time and shall be conducted by the Euro Stabilizing Manager in accordance
with all applicable laws and directives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(t) To hereby confirm the appointment of J.P. Morgan AG in its role as
stabilizing manager (the &#147;<U>Dollar Stabilizing Manager</U>&#148;) as the central point responsible for adequate public disclosure of information, and handling any request from a competent authority, in accordance with Article 6(5) of
Commission Delegated Regulation (EU) 2016/1052 of 8&nbsp;March 2016 supplementing Regulation (EU) No.&nbsp;596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the conditions applicable to buyback
programs and stabilization measures. The Dollar Stabilizing Manager for its own account may, to the extent permitted by applicable laws and directives, over-allot and effect transactions with a view to supporting the market price of the Dollar
Securities at a level higher than that which might otherwise prevail, but in doing so the Dollar Stabilizing Manager shall act as principal and not as agent of the Dollar Notes Issuer or the Guarantor and any loss resulting from overallotment and
stabilization shall be borne, and any profit arising therefrom shall be beneficially retained, by the Dollar Stabilizing Manager. However, there is no assurance that the Dollar Stabilizing Manager (or persons acting on behalf of the Dollar
Stabilizing Manager) will undertake any stabilization action. Nothing contained in this paragraph shall be construed so as to require the Dollar Notes Issuer to issue, or the Guarantor to guarantee, in excess of (i) $1,000,000,000 in aggregate
principal amount of the 2027 Dollar Notes or (ii) $1,000,000,000 in aggregate principal amount of the 2029 Dollar Notes. Such stabilization, if commenced, may be discontinued at any time and shall be conducted by the Dollar Stabilizing Manager in
accordance with all applicable laws and directives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <I>Expenses.</I> Each of the Issuers (except for the expenses in
Section&nbsp;4(f), which are applicable only to the Euro Notes Issuer) and the Guarantor, jointly and severally, agree to pay: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) the costs incident to the authorization, issuance, sale and delivery of the Securities, and any taxes payable in that
connection; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) the costs incident to the preparation, printing and distribution of the Prospectus and any amendment or
supplement to the Prospectus (including any Preliminary Prospectus) or the Registration Statement and any Issuer Free Writing Prospectus, all as provided in this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) the costs of producing and distributing the Operative Documents; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) the fees and expenses of Kirkland &amp; Ellis LLP
(&#147;<U>Kirkland</U>&#148;), Tulchinsky Marciano Cohen Levitski&nbsp;&amp; Co. Law Offices (&#147;<U>Tulchinsky</U>&#148;), Van Doorne N.V. (&#147;<U>Van Doorne</U>&#148;) and Kesselman&nbsp;&amp; Kesselman; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) the costs of distributing the terms of agreement relating to the organization of the underwriting syndicate and selling
group to the members thereof by mail or other means of communication and any transfer and stamp tax on the Securities due upon resale by the Underwriters of Securities purchased under this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) all fees incurred in connection with the listing of the Euro Securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) all travel costs for personnel of the Issuers and the Guarantor (but excluding travel expenses of the Underwriters
relating to the road show) and the costs associated with any chartered plane used in connection with the road show; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)
all fees and expenses incurred in connection with any rating of the Securities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) the costs of preparing the
Securities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) the fees and expenses (including fees and disbursements of counsel) of the Trustee, and the costs and
charges of any registrar, transfer agent, paying agent or calculation agent; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) all fees and expenses incurred in
connection with sustainability-linked structuring of the Securities, including but not limited to the sustainability-linked financial framework and second party opinions; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) all other costs and expenses incidental to the performance of the obligations of the Issuers and the Guarantor under this
Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that, except as provided in Sections 4, 7 and 10, the Underwriters shall pay their own costs and expenses,
including the costs and expenses of their counsel, which costs and expenses shall be divided <I>pro rata</I> among the Underwriters in the proportions that the total aggregate principal amount of Securities set opposite the name of each Underwriter
in Schedule I bears to the total aggregate principal amount of Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <I>Conditions of the Underwriters&#146; Obligations</I>. The several obligations of the
Underwriters hereunder are subject to the accuracy, at the Execution Time and on the Delivery Date, of the representations and warranties of each of the Issuers and the Guarantor contained herein, to the performance by each of the Issuers and the
Guarantor of its obligations hereunder, and to each of the following additional terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) No Underwriter
shall have discovered and disclosed to the Issuers or the Guarantor prior to or on the Delivery Date that the Disclosure Package, the Prospectus or any amendment or supplement thereto contains any untrue statement of a fact which, in the opinion of
counsel to the Underwriters, is material or omits to state any fact which is material and necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or that the Registration
Statement or any amendment thereto contains any untrue statement of a fact which, in the opinion of counsel to the Underwriters, is material or omits to state any fact which is material and necessary to make the statements therein not misleading.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Prospectus shall have been timely filed with the Commission in accordance with Section&nbsp;3(a) of this
Agreement; the final term sheet contemplated by Section&nbsp;3(c) hereof, and any other material required to be filed by the Guarantor pursuant to Rule 433(d) of the Rules and Regulations shall have been filed with the Commission within the
applicable time periods prescribed for such filings by Rule 433 of the Rules and Regulations; no stop order suspending the effectiveness of the Registration Statement or any part thereof or any notice that objects to or would prevent its use shall
have been issued and no proceeding for that purpose shall have been initiated or, to the knowledge of any of the parties hereto, threatened by the Commission; and any request of the Commission for inclusion of additional information in the
Registration Statement or the Prospectus or otherwise shall have been complied with in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) All
corporate proceedings and other legal matters incident to the authorization, form and validity of the Operative Documents and the Prospectus or any amendment or supplement thereto, and all other legal matters relating to the Operative Documents and
the transactions contemplated thereby shall be satisfactory in all material respects to counsel to the Underwriters, and the Issuers and the Guarantor shall have furnished to such counsel all documents and information that they may reasonably
request to enable them to pass upon such matters. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) Kirkland shall have furnished to the Underwriters their written
opinion and negative assurance letter, as U.S. counsel to the Issuers and the Guarantor, addressed to the Underwriters and dated such Delivery Date, in form and substance satisfactory to the Representatives, to the effect set forth in Exhibit A
hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Van Doorne shall have furnished to the Underwriters their written
opinion, as Netherlands counsel to the Issuers and the Guarantor, addressed to the Underwriters and dated such Delivery Date, in form and substance satisfactory to the Representatives, to the effect set forth in Exhibit B hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Tulchinsky shall have furnished to the Underwriters their written opinion, as Israeli counsel to the Guarantor, addressed
to the Underwriters and dated such Delivery Date, in form and substance satisfactory to the Representatives, to the effect set forth in Exhibit C hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) David M. Stark, Executive Vice President and Chief Legal Officer of the Guarantor, shall have furnished to the
Underwriters his written opinion addressed to the Underwriters and dated such Delivery Date, in form and substance satisfactory to the Representatives, to the effect set forth in Exhibit D hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) Baker&nbsp;&amp; McKenzie LLP shall have furnished to the Underwriters their written opinion and negative assurance
letter, as U.S. counsel to the Underwriters, addressed to the Underwriters and dated such Delivery Date, in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) Herzog, Fox&nbsp;&amp; Neeman shall have furnished to the Underwriters their written opinion, as Israeli counsel to the
Underwriters, addressed to the Underwriters and dated such Delivery Date, in form and substance satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j) Kesselman&nbsp;&amp; Kesselman, independent auditors for the Guarantor, shall have delivered to the Underwriters a
customary &#147;comfort letter&#148; in form and substance satisfactory to the Underwriters and dated as of the Execution Time (the &#147;<U>K&amp;K initial letter</U>&#148;), and a letter addressed to the Underwriters and dated as of the Delivery
Date (the &#147;<U>K&amp;K bring-down letter</U>&#148;), (i) confirming that they are the independent registered accounting firm with respect to the Guarantor within the meaning of the Securities Act and the Rules and Regulations, (ii)&nbsp;stating,
as of the date of the K&amp;K bring-down letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the Prospectus or the Disclosure Package, as of a date
not more than five days prior to the date of the K&amp;K bring-down letter), the conclusions and findings of such firm with respect to the financial information and other matters covered by the K&amp;K initial letter and (iii)&nbsp;confirming in all
material respects the conclusions and findings set forth in the K&amp;K initial letter. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k) Each of the Issuers shall have furnished to the Representatives on the
Delivery Date a certificate, dated such Delivery Date and delivered on behalf of each of the Issuers by one of its managing or supervisory directors or a duly authorized
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact,</FONT></FONT> in form and substance satisfactory to the Underwriters, to the effect that the representations and warranties of such Issuer in Section&nbsp;1 are true
and correct as of the date given and as of such Delivery Date and such Issuer has complied in all material respects with all its agreements contained herein to be performed prior to or on such Delivery Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l) The Guarantor shall have furnished to the Representatives on the Delivery Date a certificate, dated such Delivery Date and
delivered on behalf of the Guarantor by its chief executive officer, chief operating officer, chief financial officer or senior vice president, corporate treasurer, in form and substance satisfactory to the Underwriters, to the effect that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The representations and warranties of the Guarantor in Section&nbsp;1 are true and correct as of the date given and as of
such Delivery Date; and the Guarantor has complied in all material respects with all its agreements contained herein to be performed prior to or on such Delivery Date; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) (A) Except as would not have a Material Adverse Effect, the Guarantor has not sustained since the date of the latest
audited financial statements incorporated by reference in the Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, except (x)&nbsp;as set forth or contemplated in the Prospectus or the Disclosure Package (exclusive of any amendments or supplements thereto) and (y)&nbsp;for operating losses incurred in the ordinary course of
business, and (B)&nbsp;since such date there has not been any change in the capital stock or long-term debt of the Guarantor (except for issuances of shares of Ordinary Shares upon exercise of outstanding options described in the Disclosure Package
or pursuant to Authorized Grants), except as set forth or contemplated in the Prospectus or the Disclosure Package (exclusive of any amendments or supplements thereto), or any change, or any development involving a prospective change, that would
have a Material Adverse Effect; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Such officer has carefully examined the Prospectus and the Disclosure Package,
in such officer&#146;s opinion (A)&nbsp;each of&nbsp;the Prospectus and the Disclosure Package, as of its date and the Execution Time, respectively, did not include any untrue statement of a material fact and did not omit to state any material fact
necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, and (B)&nbsp;since the date of the Prospectus, no event has occurred which should have been set forth in a supplement or
amendment to the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m) Each of the Supplemental Indentures shall have been duly executed and
delivered by each of the Issuer party thereto, the Guarantor, the Trustee and any paying agent (if applicable); and the Notes and the Guarantees shall have been duly executed and delivered by each of the Issuer party thereto and the Guarantor,
respectively, and duly authenticated by the Trustee. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n) Since the date of the latest audited financial statements
incorporated by reference in the Disclosure Package (exclusive of any amendment or supplement thereto), there shall not have been (i)&nbsp;any material adverse change in the Guarantor&#146;s capital stock or long-term debt, or (ii)&nbsp;any material
adverse change or development involving a prospective material adverse change, in or affecting the condition (financial or otherwise), stockholders&#146; equity or results of operations of the Guarantor and its subsidiaries, taken as a whole, except
as set forth or contemplated in each of the most recent Preliminary Prospectus and the Prospectus(exclusive of any amendment or supplement thereto), the effect of which, in any such case described in clause (i)&nbsp;or (ii), is, in the reasonable
judgment of the Representatives, so material and adverse as to make it impracticable or inadvisable to proceed with the sale or the delivery of the Securities being delivered on the Delivery Date on the terms and in the manner contemplated in the
Disclosure Package and the Prospectus (exclusive of any amendment or supplement thereto) and any Issuer Free Writing Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o) Each of the Issuers and the Guarantor shall have furnished to the Representatives such further information, certificates
and documents as the Representatives may reasonably request to evidence compliance with the conditions set forth in this Section&nbsp;5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p) All opinions, letters, evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in
compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel to the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.
<I>Representations, Warranties and Agreements of Underwriters.</I> Each Underwriter, severally and not jointly, represents, warrants to and agrees with each of the Issuers and the Guarantor that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) It has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation
or inducement to engage in investment activity (within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000 (the &#147;<U>FSMA</U>&#148;)) received by it in connection with the issue or sale of the Securities in
circumstances in which Section&nbsp;21(1) of the FSMA does not apply to the Issuers or the Guarantor. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) It has complied and will comply with all applicable provisions of the
FSMA with respect to anything done by it in relation to the Securities in, from or otherwise involving the United Kingdom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) It has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Securities
to any retail investor in the United Kingdom. For the purposes of this provision the expression &#147;retail investor&#148; means a person who is one (or more) of the following: (A)&nbsp;a retail client, as defined in point (8)&nbsp;of Article 2 of
Regulation (EU) No 2017/565 as it forms part of domestic law by virtue of the EUWA; or (B)&nbsp;a customer within the meaning of the provisions of the FSMA and any rules or regulations made under the FSMA to implement Directive (EU) 2016/97, where
that customer would not qualify as a professional client, as defined in point (8)&nbsp;of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) It has not offered, sold or otherwise made available and will not offer, sell or otherwise make available any Securities
to any retail investor in the European Economic Area. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) For the purposes of this provision the expression &#147;retail
investor&#148; means a person who is one (or more) of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retail client as defined in point (11)&nbsp;of Article 4(1) of Directive 2014/65/EU (as amended,
&#147;<U>MiFID II</U>&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a customer within the meaning of Directive (EU) 2016/97 (as amended), where that customer would not qualify as
a professional client as defined in point (10)&nbsp;of Article 4(1) of MiFID II; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not a qualified investor as defined in Regulation (EU) 2017/1129. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) For the purposes of this provision the expression &#147;offer&#148; includes the communication in any form and by any
means of sufficient information on the terms of the offer and the Securities to be offered so as to enable an investor to decide to purchase or subscribe for the Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) Any offers in Canada will be made only under an exemption from the requirements to file a prospectus in the relevant
province of Canada in which the sale is made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) Any offers in the Netherlands will be made only to qualified investors
as defined in Regulation (EU) 2017/1129, as amended and as implemented from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) It will (i)&nbsp;purchase, accept delivery of and make payment for the
Securities outside the State of Israel and (ii)&nbsp;not offer or sell the Securities in the State of Israel, other than offers or sales to persons (A)&nbsp;who qualify as one of the types of investors listed in the First Addendum to the Israeli
Securities Law, subject to and in accordance with the requirements set forth in the First Addendum to the Israeli Securities Law, and (B)&nbsp;who have confirmed in writing that they are purchasing the Securities for their own account and not with a
view to, or for resale in connection with, any distribution thereof; except, to the extent permitted under the First Addendum to the Israeli Securities Law, for resale to qualified investors of the types listed therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) It will comply with applicable laws and regulations in each jurisdiction in which it acquires, offers, sells or delivers
Securities, or has in its possession or distributes any Free Writing Prospectus, the Disclosure Package, the Preliminary Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <I>Indemnification and Contribution</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) Each of the Issuers and the Guarantor, jointly and severally, shall indemnify and hold harmless each Underwriter, its
officers, employees, agents, affiliates and each person, if any, who controls any Underwriter within the meaning of the Securities Act, from and against any loss, claim, damage or liability, joint or several, or any action in respect thereof
(including, but not limited to, any loss, claim, damage, liability or action relating to purchases and sales of the Securities), to which that Underwriter, officer, employee, agent, affiliate or controlling person may become subject, insofar as such
loss, claim, damage, liability or action arises out of, or is based upon: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any untrue statement or alleged untrue
statement of a material fact contained in the Prospectus, the Preliminary Prospectus, the Registration Statement, any Issuer Free Writing Prospectus, any materials used by the Issuers or the Guarantor in meetings with investors (including any
electronic road show), or the information contained in the final term sheet required to be prepared and filed pursuant to Section&nbsp;3(c) hereto, or in any amendment or supplement thereto; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the omission or alleged omission to state therein any material fact
necessary to make the statements therein not misleading, and shall reimburse each Underwriter and each such officer, employee, agent, affiliate and controlling person promptly upon demand for any legal or other expenses reasonably incurred by that
Underwriter, officer, employee, agent, affiliate or controlling person in connection with investigating or defending or preparing to defend against any such loss, claim, damage, liability or action as such expenses are incurred; <U>provided</U>,
<U>however</U>, that neither of the Issuers nor the Guarantor shall be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out of, or is based upon, any untrue statement or alleged untrue statement or
omission or alleged omission made in the Preliminary Prospectus, the Prospectus, the Registration Statement, any Issuer Free Writing Prospectus, any materials used by the Issuers or the Guarantor in meetings with investors (including any electronic
road show), or the information contained in the final term sheet required to be prepared and filed pursuant to Section&nbsp;3(c) hereto, or in any such amendment or supplement thereto, in reliance upon and in conformity with the written information
furnished to the Issuers or the Guarantor by or on behalf of any Underwriter specifically for inclusion therein and described in Section&nbsp;7(e). The foregoing indemnity agreement is in addition to any liability that the Issuers or the Guarantor
may otherwise have to any Underwriter or to any officer, employee, agent, affiliate or controlling person of that Underwriter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter, severally and not jointly, shall indemnify and hold harmless, each of the Issuers and the Guarantor, its
officers and directors, agents, employees and each person, if any, who controls each of the Issuers or the Guarantor within the meaning of the Securities Act from and against any loss, claim, damage or liability, joint or several, or any action in
respect thereof, to which the Issuers or the Guarantor or their respective directors, officers, agents, employees or controlling persons may become subject, insofar as such loss, claim, damage, liability or action arises out of, or is based upon:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) any untrue statement or alleged untrue statement of a material fact contained in the Prospectus, the Preliminary
Prospectus, any Issuer Free Writing Prospectus or the information contained in the final term sheet required to be prepared and filed pursuant to Section&nbsp;3(c) hereto, or in any amendment or supplement thereto; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the omission or alleged omission to state therein any material fact necessary to make the statements therein not
misleading, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">but in each case only to the extent that such untrue statement or alleged untrue statement or omission or alleged omission was made in
reliance upon and in conformity with the written information furnished to the Issuers or the Guarantor by or on behalf of that Underwriter specifically for inclusion therein and described in Section&nbsp;7(e), and shall reimburse the Issuers and the
Guarantor and any such director, officer, agent, employee or controlling person promptly upon demand for any legal or other expenses reasonably incurred by the Issuers or the Guarantor or any such director, officer, agent, employee or controlling
person in connection with investigating or defending or preparing to defend against any such loss, claim, damage, liability or action as such expenses are incurred. The foregoing indemnity agreement is in addition to any liability which any
Underwriter may otherwise have to the Issuers, the Guarantor or any such director, officer, agent, employee or controlling person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this
Section&nbsp;7 of notice of any claim or the commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;7, notify the indemnifying party in writing of
the claim or the commencement of that action; <U>provided</U>,<U> however</U>, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this Section&nbsp;7 except to the extent it has been
materially prejudiced by such failure; and, <U>provided</U>, <U>further</U>, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this
Section&nbsp;7. If any such claim or action shall be brought against an indemnified party, and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly
with any other similarly notified indemnifying party, to assume the defense thereof with counsel satisfactory to the indemnified party. After notice from the indemnifying party to the indemnified party of its election to assume the defense of such
claim or action, the indemnifying party shall not be liable to the indemnified party under this Section&nbsp;7 for any legal or other expenses subsequently incurred by the indemnified party in connection with the defense thereof other than
reasonable costs of investigation; <U>provided</U>, <U>however</U>, that the Underwriters shall have the right to employ counsel to represent jointly the Underwriters and their respective officers, employees, agents, affiliates and controlling
persons who may be subject to liability arising out of any claim in respect of which indemnity may be sought by the Underwriters against the Issuers under this Section&nbsp;7, if the Underwriters shall have reasonably concluded that there may be one
or more legal defenses available to the Underwriters and their respective officers, employees, agents, affiliates and controlling persons that are different from or additional to those available to the Issuers and the Guarantor and their respective
officers, directors, employees, agents, affiliates and controlling persons, and the reasonable fees and expenses of a single separate counsel shall be paid, jointly and severally, by each of the Issuers and the Guarantor. No indemnifying party
shall: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) without the prior written consent of the indemnified parties (which consent shall not be unreasonably withheld)
settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified
parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent (A)&nbsp;includes an unconditional release of each indemnified party from all liability arising out of such claim, action, suit or
proceeding and (B)&nbsp;does not include any statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) be liable for any settlement of any such action effected without its written consent (which consent shall not be
unreasonably withheld), but if settled with its written consent or if there be a final judgment for the plaintiff in any such action, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or
liability by reason of such settlement or judgment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this Section&nbsp;7 shall for
any reason be unavailable or insufficient to hold harmless an indemnified party under Section&nbsp;7(a) or 7(b) in respect of any loss, claim, damage or liability, or any action in respect thereof, referred to therein, each indemnifying party shall,
in lieu of indemnifying such indemnified party, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) in such proportion as shall be appropriate to reflect the relative benefits received by the Issuers and the Guarantor on
the one hand and the Underwriters on the other from the offering of the Securities, or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) if the allocation provided by
clause 7(d)(i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause 7(d)(i) but also the relative fault of the Issuers and the Guarantor on the one hand and the
Underwriters on the other with respect to the statements or omissions or alleged statements or alleged omissions that resulted in such loss, claim, damage or liability (or action in respect thereof), as well as any other relevant equitable
considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The relative benefits received by the Issuers and the Guarantor on the one hand and the Underwriters on the other with respect to such
offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Securities purchased under this Agreement (before deducting expenses) received by the Issuers on the one hand, and the total discounts and
commissions received by the Underwriters with respect to the Securities purchased under this Agreement, on the other hand, bear to the total gross proceeds from the offering of the Securities under this Agreement, in each case as set forth in the
table on the cover page of the Prospectus. The relative fault shall be determined by reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information
supplied by the Issuers or the Guarantor on the one hand or the Underwriters on the other, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Issuers,
the Guarantor and the Underwriters agree that it would not be just and equitable if the amount of contributions pursuant to this Section&nbsp;7(d) were to be determined by <U>pro</U><I> </I><U>rata</U> allocation (even if the Underwriters were
treated as one entity for such purpose) or by any other method of allocation which does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage
or liability, or action in respect thereof, referred to above in this Section&nbsp;7(d) shall be deemed to include, for purposes of this Section&nbsp;7(d), any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;7(d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Securities resold
by it in the initial placement of such Securities were offered to investors exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters&#146; obligations to contribute as provided in this Section&nbsp;7(d) are several in proportion to their respective purchase obligations and not joint. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Underwriters severally confirm that the statements with respect to
the delivery of the Securities set forth on the cover page of the Prospectus and the Preliminary Prospectus and the first paragraph under the <FONT STYLE="white-space:nowrap">sub-caption</FONT> &#147;Price Stabilization and Short Positions&#148; and
the allocation table under the caption &#147;Underwriting&#148; in the Prospectus and the most recent Preliminary Prospectus are correct and constitute the only information furnished in writing to the Issuers and the Guarantor by or on behalf of the
Underwriters specifically for inclusion in the most recent Preliminary Prospectus, the Prospectus, any Issuer Free Writing Prospectus or the information contained in the final term sheet required to be prepared and filed pursuant to
Section&nbsp;3(c) hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <I>Defaulting Underwriters</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If, on the Delivery Date, any Euro Underwriter defaults in the performance of its obligations under this Agreement, the remaining <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Euro Underwriters shall be obligated to purchase the aggregate principal amount of such series of Euro Securities which the defaulting Euro Underwriter agreed but failed to purchase on such Delivery
Date in the respective proportions which the total aggregate principal amount of such series of Euro Securities set opposite the name of each remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Euro Underwriter in Part A of Schedule I
hereto bears to the total aggregate principal amount of such series of Euro Securities set opposite the names of all the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Euro Underwriters in Part A of Schedule I hereto;
<U>provided</U>, <U>however</U>, that the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Euro Underwriters shall not be obligated to purchase any such series of Euro Securities on such Delivery Date if the total aggregate principal
amount of such series of Euro Securities which the defaulting Euro Underwriters agreed but failed to purchase on such date exceeds 10.0% of the total aggregate principal amount of such series of Euro Securities to be purchased on such Delivery Date,
and any remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Euro Underwriter shall not be obligated to purchase more than 110.0% of the aggregate principal amount of any series of Euro Securities which it agreed to purchase on such
Delivery Date pursuant to the terms of Section&nbsp;2. If the foregoing maximums are exceeded, the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Euro Underwriters, or those other purchasers satisfactory to the Euro Underwriters
who so agree, shall have the right, but shall not be obligated, to purchase on such Delivery Date, in such proportion as may be agreed upon among them, the total aggregate principal amount of any series of Euro Securities to be purchased on such
Delivery Date. If the remaining Euro Underwriters or other purchasers satisfactory to the Euro Underwriters do not elect to purchase on such Delivery Date the aggregate principal amount of the series of Euro Securities which the defaulting Euro
Underwriters agreed but failed to purchase, this Agreement shall terminate with respect to the Euro Underwriters without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Euro Underwriters and the Issuers and the
Guarantor, except that the Issuers and the Guarantor will continue to be liable for the payment of expenses to the extent set forth in Sections 4 and 10. As used in this Agreement, the term &#147;<U>Euro Underwriter</U>&#148; includes, for all
purposes of this Agreement unless the context requires otherwise, any party not listed in Part A of Schedule I hereto who, pursuant to this Section&nbsp;8, purchases any series of Euro Securities which a defaulting Euro Underwriter agreed but failed
to purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If, on the Delivery Date, any Dollar Underwriter defaults in the performance of its
obligations under this Agreement, the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Dollar Underwriters shall be obligated to purchase the aggregate principal amount of such series of Dollar Securities which the defaulting Dollar
Underwriter agreed but failed to purchase on such Delivery Date in the respective proportions which the total aggregate principal amount of such series of Dollar Securities set opposite the name of each remaining
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Dollar Underwriter in Part B of Schedule I hereto bears to the total aggregate principal amount of such series of Dollar Securities set opposite the names of all the remaining <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Dollar Underwriters in Part B of Schedule I hereto; <U>provided</U>, <U>however</U>, that the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Dollar Underwriters shall not be
obligated to purchase any such series of Dollar Securities on such Delivery Date if the total aggregate principal amount of such series of Dollar Securities which the defaulting Dollar Underwriters agreed but failed to purchase on such date exceeds
10.0% of the total aggregate principal amount of such series of Dollar Securities to be purchased on such Delivery Date, and any remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Dollar Underwriter shall not be obligated to purchase
more than 110.0% of the aggregate principal amount of any series of Dollar Securities which it agreed to purchase on such Delivery Date pursuant to the terms of Section&nbsp;2. If the foregoing maximums are exceeded, the remaining <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Dollar Underwriters, or those other purchasers satisfactory to the Dollar Underwriters who so agree, shall have the right, but shall not be obligated, to purchase on such Delivery Date, in such
proportion as may be agreed upon among them, the total aggregate principal amount of any series of Dollar Securities to be purchased on such Delivery Date. If the remaining Dollar Underwriters or other purchasers satisfactory to the Dollar
Underwriters do not elect to purchase on such Delivery Date the aggregate principal amount of the series of Dollar Securities which the defaulting Dollar Underwriters agreed but failed to purchase, this Agreement shall terminate with respect to the
Dollar Underwriters without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Dollar Underwriters and the Issuers and the Guarantor, except that the Issuers and the Guarantor will continue to be liable for the
payment of expenses to the extent set forth in Sections 4 and 10. As used in this Agreement, the term &#147;<U>Dollar Underwriter</U>&#148; includes, for all purposes of this Agreement unless the context requires otherwise, any party not listed in
Part B of Schedule I hereto who, pursuant to this Section&nbsp;8, purchases any series of Dollar Securities which a defaulting Dollar Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Issuers for damages caused by its default.
If other purchasers are obligated or agree to purchase the Securities of a defaulting or withdrawing Underwriter, either the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Issuers may postpone the Delivery Date
for up to seven full business days in order to effect any changes in the Prospectus or in any other document or arrangement that, in the opinion of counsel to the Issuers and the Guarantor or counsel to the Underwriters, may be necessary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <I>Termination.</I> The obligations of the Underwriters hereunder may be terminated by
the Representatives by notice given to and received by the Issuers and the Guarantor prior to delivery of and payment for the Securities, after the execution and delivery of this Agreement and prior to the Delivery Date, any of the following events
shall have occurred (i)&nbsp;trading in securities generally on the New York Stock Exchange, or trading in any securities of the Guarantor on any exchange shall have been suspended or minimum prices shall have been established on any such exchange
or market by the Commission, by such exchange or by any other regulatory body or governmental authority having jurisdiction; (ii)&nbsp;a banking moratorium shall have been declared by United States federal or New York State authorities or a material
disruption shall have occurred in commercial banking or securities settlement or clearance services in the United States; (iii)&nbsp;there shall have occurred any outbreak or escalation in hostilities involving the United States, or there shall have
been a declaration of a national emergency or war by the United States or The Netherlands; (iv)&nbsp;the rating accorded the Guarantor&#146;s debt securities shall have been downgraded by any &#147;nationally recognized statistical rating
organization,&#148; as that term is defined in Section&nbsp;3(a)(62) of the Exchange Act, or such an organization shall have made any public announcement that it has under surveillance or review, with possible negative implications for a downgrade,
its rating of any of the Guarantor&#146;s debt securities; or (v)&nbsp;there shall have occurred such a material adverse change in general economic, political or financial conditions (or the effect of international conditions on the financial
markets in the United States, The Netherlands or Israel shall be such) as to make it, with respect to the events in clause (iii)&nbsp;or (v) in the sole judgment of the Representatives, impracticable or inadvisable to proceed with the offering or
delivery of the Securities being delivered on such Delivery Date on the terms and in the manner contemplated in the Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <I>Reimbursement of Underwriters&#146; Expenses.</I> If (a)&nbsp;either of the Issuers and the Guarantor shall fail to tender the
Securities for delivery to the Underwriters for any reason permitted under this Agreement or (b)&nbsp;the Underwriters shall decline to purchase the Securities because of any failure or refusal on the part of either of the Issuers or the Guarantor
to comply with the terms or to fulfill any of the conditions of this Agreement or if either of the Issuers or the Guarantor shall be unable to perform its obligations under this Agreement, the relevant Issuer(s) and the Guarantor, jointly and
severally, shall reimburse the Underwriters for the fees and expenses of their counsel and for such other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses as shall have been incurred by them in
connection with this Agreement and the proposed purchase of the Securities, and upon demand the relevant Issuer(s) shall pay the full amount thereof to the Underwriters. If this Agreement is terminated pursuant to Section&nbsp;8 by reason of the
default of one or more Underwriters, the relevant Issuer(s) shall not be obligated to reimburse any defaulting Underwriter on account of those expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11. <I>Notices, etc.</I> All statements, requests, notices and agreements hereunder shall be in writing, and: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) if to the Euro Underwriters or the Euro Representatives, shall be delivered or sent by mail to BofA Securities Europe SA,
51 rue La Bo&eacute;tie, 75008 Paris, France, Attention: High Yield Syndicate Desk (Tel: +3318770 0000, email: levfin_hy_paris@bofa.com); BNP Paribas, 16, boulevard des Italiens, 75009 Paris, France, Attention: Fixed Income Syndicate (email:
dl.syndsupportbonds@bnpparibas.com); HSBC Bank plc, 8 Canada Square, London E14 5HQ, United Kingdom, Attention: Transaction Management EMEA Debt Capital Markets (Fax: +44 20 7992 4973) and J.P. Morgan AG, Taunustor 1 (TaunusTurm), 60310 Frankfurt am
Main, Germany (Email: emea_syndicate@jpmorgan.com), Attention: Head of International Syndicate; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) if to the Dollar Underwriters or the Dollar Representatives, shall be
delivered or sent by mail to BofA Securities, Inc., One Bryant Park, New York, New York 10036, United States of America, Attention: Legal Department (fax: +1 212 901 7897); BNP Paribas Securities Corp., 787 Seventh Avenue, New York, New York 10019,
USA, Attention: Syndicate Desk (email: new.york.syndicate@bnpparibas.com); HSBC Bank plc, 8 Canada Square, London E14 5HQ, United Kingdom, Attention: Transaction Management EMEA Debt Capital Markets (Fax: +44 20 7992 4973) and J.P. Morgan AG,
Taunustor 1 (TaunusTurm), 60310 Frankfurt am Main, Germany (Email: emea_syndicate@jpmorgan.com), Attention: Head of International Syndicate; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) if to the Guarantor, shall be delivered or sent by mail or facsimile transmission to Teva Pharmaceutical Industries
Limited, 124 Dvora Hanevi&#146;a Street, Tel Aviv, 6944020, Israel, Attention: Stephen Harper (Fax: **********), with copies (which shall not constitute notice) to: (i)&nbsp;Teva Pharmaceuticals USA, Inc., 400 Interpace Parkway, Building A
Parsippany, New Jersey 07054, Attention: David M. Stark (Fax: **********); and (ii)&nbsp;Kirkland&nbsp;&amp; Ellis LLP, 601 Lexington Avenue, New York, NY, 10022, Attention: Joshua Korff and Ross Leff (Fax: **********); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) if to the Euro Notes Issuer, shall be delivered or sent by mail or facsimile transmission to Teva Pharmaceutical Finance
Netherlands II B.V., Piet Heinkade 107, 1019 GM, Amsterdam, Netherlands, Attention: Managing Director, with copies (which shall not constitute notice) to: (i)&nbsp;c/o Teva Pharmaceuticals USA, Inc., 400 Interpace Parkway, #3 Parsippany, New Jersey
07054, Attention: David M. Stark (Fax: **********) and (ii)&nbsp;Kirkland&nbsp;&amp; Ellis LLP, 601 Lexington Avenue, New York, NY, 10022, Attention: Joshua Korff and Ross Leff (Fax: **********) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) if to the Dollar Notes Issuer, shall be delivered or sent by mail or facsimile transmission to Teva Pharmaceutical Finance
Netherlands III B.V., Piet Heinkade 107, 1019 GM, Amsterdam, Netherlands, Attention: Managing Director, with copies (which shall not constitute notice) to: (i)&nbsp;c/o Teva Pharmaceuticals USA, Inc., 400 Interpace Parkway, #3 Parsippany, New Jersey
07054, Attention: David M. Stark (Fax: **********) and (ii)&nbsp;Kirkland&nbsp;&amp; Ellis LLP, 601 Lexington Avenue, New York, NY, 10022, Attention: Joshua Korff and Ross Leff (Fax: **********); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U>, <U>however</U>, that any notice to an Underwriter pursuant to Section&nbsp;7(c) shall be
delivered or sent by mail or facsimile transmission to each such Underwriter, which address will be supplied to any other party hereto by the Representatives upon request. Any such statements, requests, notices or agreements shall take effect at the
time of receipt thereof. The Issuers and the Guarantor shall be entitled to act and rely upon any request, consent, notice or agreement given or made on behalf of the Underwriters by the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12. <I>Persons Entitled to Benefit of Agreement.</I> This Agreement shall inure to the benefit of and be binding upon the Underwriters, the
Issuers, the Guarantor and their respective successors. This Agreement and the terms and provisions hereof are for the sole benefit of only those persons, except that the representations, warranties, indemnities and agreements of the Issuers and the
Guarantor contained in this Agreement shall also be deemed to be for the benefit of the officers, employees, agents and affiliates of each Underwriter and the person or persons, if any, who control each Underwriter within the meaning of
Section&nbsp;15 of the Securities Act and any indemnity agreement of the Underwriters contained in Section&nbsp;7(b) of this Agreement shall be deemed to be for the benefit of directors, officers, employees, agents and affiliates of the Issuers and
the Guarantor, and any person controlling the Issuers or the Guarantor within the meaning of Section&nbsp;15 of the Securities Act. Nothing contained in this Agreement is intended or shall be construed to give any person, other than the persons
referred to in this Section&nbsp;12, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. <I>Survival</I>. The respective indemnities, representations, warranties and agreements of the Issuers, the Guarantor and the Underwriters
contained in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination or
cancellation of this Agreement or any investigation made by or on behalf of any of them or any person controlling any of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14.
<I>Transfers to EU Affiliates. </I>Notwithstanding anything to the contrary in this Agreement, each Underwriter (whether it is an original party to this Agreement or a party to whom this Agreement has been previously transferred pursuant to this
paragraph) shall be entitled to assign or transfer all of its rights or obligations under this Agreement to any affiliate registered in the European Union or which is also carrying on <FONT STYLE="white-space:nowrap">EU-regulated</FONT> services (in
each case, the &#147;<U>EU Affiliate</U>&#148;) by notice in writing, and from the date of such transfer, references to such Underwriter shall be read as references to such EU Affiliate. Upon completion of such assignment or transfer of all rights
and obligations under this Agreement, each transferor pursuant to this Section&nbsp;14 shall be released from its obligations under this letter agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. <I>No Fiduciary Duty</I>. The Issuers and the Guarantor hereby acknowledge that
(a)&nbsp;the purchase and sale of the Securities pursuant to this Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Issuers and the Guarantor, on the one hand, and the Underwriters and any
affiliate through which they may be acting, on the other, (b)&nbsp;the Underwriters are acting as principal and not as an agent or fiduciary of the Issuers and the Guarantor and (c)&nbsp;the engagement of the Underwriters by the Issuers and the
Guarantor in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity. Furthermore, each of the Issuers and the Guarantor agrees that it is solely responsible for making its
own judgments in connection with the offering (irrespective of whether any of the Underwriters has advised or is currently advising the Issuers or the Guarantor on related or other matters). Each of the Issuers and the Guarantor agrees that it will
not claim that the Underwriters have rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Issuers and the Guarantor, in connection with such transaction or the process leading thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16. <I><FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding and to the exclusion of any other term of this Agreement or any other agreement, arrangement, or
understanding between or among the Issuers and the Guarantors and an Underwriter incorporated in the EU (the &#147;<U>Relevant BRRD Party</U>&#148;), the Issuers and the Guarantor acknowledge and accept that a BRRD Liability arising under this
Agreement may be subject to the exercise of <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the Relevant Resolution Authority, and acknowledges, accepts and agrees to be bound by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the effect of the exercise of <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the Relevant Resolution Authority
in relation to any BRRD Liability of the Relevant BRRD Party to the Issuers or the Guarantor, as applicable, under this Agreement, that (without limitation) may include and result in any of the following, or some combination thereof: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the reduction of all, or a portion, of the BRRD Liability or outstanding amounts due thereon;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conversion of all, or a portion, of the BRRD Liability into shares, other securities or other obligations
of the Relevant BRRD Party or another person, and the issue to or conferral on the Issuers or the Guarantor of such shares, securities or obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the cancellation of the BRRD Liability; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amendment or alteration of any interest, if applicable, thereon or the dates on which any payments are due,
including by suspending payment for a temporary period; and </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the variation of the terms of this
Agreement, as deemed necessary by the Relevant Resolution Authority, to give effect to the exercise of <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the Relevant Resolution Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) For purposes of this Section&nbsp;16(a): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation</U>&#148; means in relation to a member
state of the European Economic Area which has implemented, or which at any time implements, the BRRD, the relevant implementing law, regulation, rule or requirement as described in the EU <FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation
Schedule from time to time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U><FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers</U>&#148; means any Write-down and Conversion
Powers as defined in the EU <FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation Schedule, in relation to the relevant <FONT STYLE="white-space:nowrap">Bail-In</FONT> Legislation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>BRRD</U>&#148; means Directive 2014/59/EU establishing a framework for the recovery and resolution of
credit institutions and investment firms, as amended or superseded; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>BRRD Liability</U>&#148; means a liability in respect of which the relevant Write-down and Conversion
Powers in the applicable <FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation may be exercised; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>EU <FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation Schedule</U>&#148; means the document
described as such, then in effect, and published by the Loan Market Association (or any successor person) from time to time at http://www.lma.eu.com/pages.aspx?p=499; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Relevant Resolution Authority</U>&#148; means the resolution authority with the ability to exercise
any <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers in relation to the Relevant BRRD Party. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
Notwithstanding and to the exclusion of any other term of this Agreement or any other agreement, arrangement, or understanding between or among the Issuers and the Guarantor and an Underwriter incorporated in the UK (the &#147;<U>Relevant <FONT
STYLE="white-space:nowrap">Bail-in</FONT> Party</U>&#148;), the Issuers and the Guarantor acknowledge and accept that a UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability arising under this Agreement may be subject to the exercise of UK <FONT
STYLE="white-space:nowrap">Bail-in</FONT> Powers by the Relevant UK Resolution Authority, and acknowledges, accepts and agrees to be bound by: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the effect of the exercise of UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the Relevant UK Resolution
Authority in relation to any UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability of any Relevant <FONT STYLE="white-space:nowrap">Bail-in</FONT> Party to the Company under this Agreement, that (without limitation) may include and result in
any of the following, or some combination thereof: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the reduction of all, or a portion, of the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability or
outstanding amounts due thereon; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conversion of all, or a portion, of the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability into
shares, other securities or other obligations of the Relevant <FONT STYLE="white-space:nowrap">Bail-in</FONT> Party or another person, and the issue to or conferral on the Issuers or the Guarantor of such shares, securities or obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the cancellation of the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability; and
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amendment or alteration of any interest, if applicable, thereon or the dates on which any payments are due,
including by suspending payment for a temporary period; and </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the variation of the terms of this
Agreement, as deemed necessary by the Relevant UK Resolution Authority, to give effect to the exercise of UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers by the Relevant UK Resolution Authority. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) For purposes of this Section&nbsp;16(b): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>Relevant UK Resolution Authority</U>&#148; means the resolution authority with the ability to exercise
any UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers in relation to any Relevant <FONT STYLE="white-space:nowrap">Bail-in</FONT> Party; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Legislation</U>&#148; means Part I of the UK
Banking Act 2009 and any other law or regulation applicable in the UK relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (otherwise than through liquidation, administration or
other insolvency proceedings); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Liability</U>&#148; means a liability in respect of
which the UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers may be exercised; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<U>UK <FONT STYLE="white-space:nowrap">Bail-in</FONT> Powers</U>&#148; means the powers under the UK <FONT
STYLE="white-space:nowrap">Bail-In</FONT> Legislation to cancel, transfer or dilute shares issued by a person that is a bank or investment firm or affiliate of a bank or investment firm, to cancel, reduce, modify or change the form of a liability of
such a person or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to
have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The provisions of this Section&nbsp;16 shall remain in full force and effect notwithstanding completion and shall survive
the termination or cancellation of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">17. <I>Jurisdiction.</I> Each of the Issuers and the Guarantor agrees that any suit, action
or proceeding against the Issuers or the Guarantor brought by any Underwriter, the directors, officers, employees, agents and affiliates of any Underwriter, or by any person who controls any Underwriter, arising out of or based upon this Agreement
or the offer and sale of the Securities contemplated hereby may be instituted in any State or Federal court in The City of New York, New York, and waives any objection which it may now or hereafter have to the laying of venue of any such proceeding,
and irrevocably submits to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any suit, action or proceeding. Each of the Issuers and the Guarantor has appointed Teva Pharmaceuticals USA, Inc. (&#147;<U>Teva
USA</U>&#148;) as its authorized agent (the &#147;<U>Authorized Agent</U>&#148;) upon whom process may be served in any suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated herein which may be
instituted in any State or Federal court in The City of New York, New York, by any Underwriter, the directors, officers, employees, agents and affiliates of any Underwriter, or by any person who controls any Underwriter, and expressly accepts the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of any such court in respect of any such suit, action or proceeding. Each of the Issuers and the Guarantor hereby represents and warrants that the Authorized Agent has accepted such
appointment and has agreed to act as said agent for service of process, and each of the Issuers and the Guarantor agrees to take any and all action, including the filing of any and all documents that may be necessary to continue such appointment in
full force and effect as aforesaid. Service of process upon the Authorized Agent shall be deemed, in every respect, effective service of process upon the Issuers or the Guarantor, as applicable. Notwithstanding the foregoing, any action arising out
of or based upon this Agreement may be instituted by any Underwriter, the directors, officers, employees, agents and affiliates of any Underwriter, or by any person who controls any Underwriter, in any court of competent jurisdiction in<B>
</B>Israel. EACH OF THE ISSUERS, THE GUARANTOR AND EACH OF THE UNDERWRITERS HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS
AGREEMENT OR THE OFFER AND SALE OF THE SECURITIES CONTEMPLATED HEREBY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">18. <I>Applicable Law</I>. This Agreement will be governed by and
construed in accordance with the laws of the State of New York applicable to contracts made and to be performed within the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">19. <I>Currency</I>. Each reference in this Agreement to U.S. dollars (the &#147;<U>relevant currency</U>&#148;) is of the essence. To the
fullest extent permitted by law, the obligations of each of the Issuers and the Guarantor in respect of any amount due under this Agreement will, notwithstanding any payment in any other currency (whether pursuant to a judgment or otherwise), be
discharged only to the extent of the amount in the relevant currency that the party entitled to receive such payment may, in accordance with its normal procedures, purchase with the sum paid in such other currency (after any premium and costs of
exchange) on the Business Day immediately following the day on which such party receives such payment. If the amount in the relevant currency that may be so purchased for any reason falls short of the amount originally due, the Issuers and the
Guarantor will pay such additional amounts, in the relevant currency, as may be necessary to compensate for the shortfall. Any obligation of each of the Issuers or the Guarantor not discharged by such payment will, to the fullest extent permitted by
applicable law, be due as a separate and independent obligation and, until discharged as provided herein, will continue in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">20. <I>Recognition of the U.S. Special Resolution Regimes</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special
Resolution Regime (as defined below), the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate (as
defined below) of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no
greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) For purposes of this Section&nbsp;20: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) &#147;<U>BHC Act Affiliate</U>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be
interpreted in accordance with, 12 U.S.C. &#167; 1841(k); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) &#147;<U>Covered Entity</U>&#148; means any of the
following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 252.82(b), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 47.3(b), or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R.
&#167; 382.2(b); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3) &#147;<U>Default Right</U>&#148; has the meaning assigned to that term in, and shall be interpreted
in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(4) &#147;<U>U.S. Special Resolution
Regime</U>&#148; means each of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) the Federal Deposit Insurance Act and the regulations promulgated thereunder, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">21. <I>Waiver of Immunity</I>. To the extent that either of the Issuers or the Guarantor has or hereafter may acquire any immunity (sovereign
or otherwise) from any legal action, suit or proceeding, from jurisdiction of any court or from <FONT STYLE="white-space:nowrap">set-off</FONT> or any legal process (whether service or notice, attachment in aid or otherwise) with respect to itself
or any of its property, each of the Issuers and the Guarantor hereby irrevocably waives and agrees not to plead or claim such immunity in respect of its obligations under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">22. <I>Definitions. </I>The terms which follow, as used in this Agreement, have the meanings indicated: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Base Prospectus</U>&#148; means the prospectus contained in the Registration Statement at the Effective Time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day on which the New York Stock Exchange is open for trading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Package</U>&#148; shall mean (i)&nbsp;the Base Prospectus, as amended and supplemented
to the Execution Time, (ii)&nbsp;the Issuer Free Writing Prospectuses, if any, identified in Schedule II hereto, and (iii)&nbsp;any other Free Writing Prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of
the Disclosure Package other than a road show that is an Issuer Free Writing Prospectus under Rule 433 of the Rules and Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective
Time</U>&#148; means each date and time that the Registration Statement and any post-effective amendment or amendments thereto became or become effective </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Execution Time</U>&#148; means (i) 3:29 P.M. (New York time) on November&nbsp;2, 2021 for the Euro Securities and (ii) 3:25 P.M. (New York time) on
November&nbsp;2, 2021 for the Dollar Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Free Writing Prospectus</U>&#148; shall mean a free writing prospectus, as defined in Rule 405
of the Rules and Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Incorporated Documents</U>&#148; means documents that are incorporated into any of the Registration Statement,
Prospectus or Preliminary Prospectus by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Issuer Free Writing Prospectus</U>&#148; shall mean an issuer free writing prospectus, as
defined in Rule 433 of the Rules and Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Ordinary Shares</U>&#148; shall mean fully paid, nonassessable ordinary shares of the
Guarantor, par value NIS 0.10 per share, or American Depository Shares representing such ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Preliminary Prospectus</U>&#148; shall
mean any preliminary prospectus supplement to the Base Prospectus which describes the Securities and the offering thereof and is used prior to filing of the final Prospectus, together with the Base Prospectus and any Incorporated Documents with
respect thereto </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus</U>&#148; means the prospectus and prospectus supplements first filed after the Execution Time with the Commission by
the Issuers and the Guarantor with the consent of the Representatives pursuant to Rule 424(b) of the Rules and Regulations relating to the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; means the Registration Statement of the Issuers and the Guarantor filed with the Commission on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-260519),</FONT> including any prospectus supplement relating to the Securities that is filed with the Commission pursuant to Rule 424(b) of the Rules and
Regulations and deemed part of such registration statement pursuant to Rule 430B of the Rules and Regulations, exhibits other than Forms <FONT STYLE="white-space:nowrap">T-1</FONT> and financial statements, as amended at the Execution Time and, in
the event any post-effective amendment thereto becomes effective prior to the Delivery Date, means also such registration statement as so amended </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<U>subsidiary</U>&#148; has the meaning set forth in Rule 405 of the Rules and Regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">23. <I>Compliance with USA Patriot Act. </I>Each of the Issuers and the Guarantor
acknowledge that, in accordance with the requirements of Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Pub. L
<FONT STYLE="white-space:nowrap">107-56)</FONT> (USA PATRIOT Act) (signed into law October&nbsp;26, 2001), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Issuers and the
Guarantor, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">24. <I>Counterparts.</I> This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the
executed counterparts shall each be deemed to be an original but all such counterparts shall together constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">25. <I>Headings.</I> The headings herein are inserted for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">26. <I>Electronic Signatures</I>. This Agreement may be executed in counterparts, each of
which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same instrument. Any signature to this Agreement may be delivered by facsimile, electronic mail (including pdf) or any
electronic signature complying with the U.S. federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be
valid and effective for all purposes to the fullest extent permitted by applicable law. For the avoidance of doubt, the foregoing also applies to any amendment, extension or renewal of this Agreement. Each of the parties represents and warrants to
the other party/ies that it has the corporate capacity and authority to execute this Agreement through electronic means and there are no restrictions for doing so in that party&#146;s constitutive documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the foregoing correctly sets forth the agreement between the Issuers, the Guarantor and
the Underwriters, please indicate your acceptance in the space provided for that purpose below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">T<SMALL>EVA</SMALL> P<SMALL>HARMACEUTICAL</SMALL> I<SMALL>NDUSTRIES</SMALL> L<SMALL>IMITED</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ K&aring;re Schultz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: K&aring;re Schultz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Eli Kalif</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Executive Vice President and Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">T<SMALL>EVA</SMALL> P<SMALL>HARMACEUTICAL</SMALL> F<SMALL>INANCE</SMALL> N<SMALL>ETHERLANDS</SMALL> II B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Authorized Representative</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Stephen David Harper</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Stephen David Harper</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Authorized Representative</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">T<SMALL>EVA</SMALL> P<SMALL>HARMACEUTICAL</SMALL> F<SMALL>INANCE</SMALL> N<SMALL>ETHERLANDS</SMALL> III B.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: David Vrhovec</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Authorized Representative</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Stephen David Harper</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Stephen David Harper</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Authorized Representative</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL>
A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>)<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B<SMALL>OF</SMALL>A S<SMALL>ECURITIES</SMALL> E<SMALL>UROPE</SMALL> SA </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP P<SMALL>ARIBAS</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC B<SMALL>ANK</SMALL>
<SMALL>PLC</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. M<SMALL>ORGAN</SMALL> AG </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Euro
Representatives </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: B<SMALL>OF</SMALL>A S<SMALL>ECURITIES</SMALL> E<SMALL>UROPE</SMALL> SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Itay Singer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Itay Singer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: BNP P<SMALL>ARIBAS</SMALL></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Hugh Pryse-Davies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Hugh Pryse-Davies</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorised Signatory</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Benedict Foster</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Benedict Foster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Authorised Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: HSBC B<SMALL>ANK</SMALL> <SMALL>PLC</SMALL></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Prateek Karamchandani</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Prateek Karamchandani</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Legal Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: J.P. M<SMALL>ORGAN</SMALL> AG</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Natalia Lutova</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Natalia Lutova</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Director</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mirek Urbanski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Mirek Urbanski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL>
A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>)<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B<SMALL>OF</SMALL>A S<SMALL>ECURITIES</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP P<SMALL>ARIBAS</SMALL> S<SMALL>ECURITIES</SMALL> C<SMALL>ORP</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC B<SMALL>ANK</SMALL> <SMALL>PLC</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P.
M<SMALL>ORGAN</SMALL> AG </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Dollar Representatives </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: B<SMALL>OF</SMALL>A S<SMALL>ECURITIES</SMALL>, I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Matthew Curtin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Matthew Curtin</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: BNP P<SMALL>ARIBAS</SMALL> S<SMALL>ECURITIES</SMALL> C<SMALL>ORP</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Roger Kim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Roger Kim</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: HSBC B<SMALL>ANK</SMALL> <SMALL>PLC</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Prateek Karamchandani</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Prateek Karamchandani</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Legal Counsel</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: J.P. M<SMALL>ORGAN</SMALL> AG</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Natalia Lutova</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Natalia Lutova</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Mirek Urbanski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Mirek Urbanski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Executive Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL>
A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>)<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>ITIGROUP</SMALL> G<SMALL>LOBAL</SMALL> M<SMALL>ARKETS</SMALL> E<SMALL>UROPE</SMALL> AG </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">G<SMALL>OLDMAN</SMALL> S<SMALL>ACHS</SMALL> B<SMALL>ANK</SMALL> E<SMALL>UROPE</SMALL> SE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">M<SMALL>IZUHO</SMALL> S<SMALL>ECURITIES</SMALL> E<SMALL>UROPE</SMALL> G<SMALL>MB</SMALL>H </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MUFG S<SMALL>ECURITIES</SMALL> (E<SMALL>UROPE</SMALL>) N.V. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I<SMALL>NTESA</SMALL> S<SMALL>ANPAOLO</SMALL> S.<SMALL>P</SMALL>.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PNC C<SMALL>APITAL</SMALL> M<SMALL>ARKETS</SMALL> LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Euro
Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: C<SMALL>ITIGROUP</SMALL> G<SMALL>LOBAL</SMALL> M<SMALL>ARKETS</SMALL> E<SMALL>UROPE</SMALL> AG</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Annabel Ballance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annabel Ballance</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Delegated Signatory</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: G<SMALL>OLDMAN</SMALL> S<SMALL>ACHS</SMALL> B<SMALL>ANK</SMALL> E<SMALL>UROPE</SMALL> SE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jens Hofmann</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jens Hofmann</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ogven Sedgwick</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ogven Sedgwick</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: M<SMALL>IZUHO</SMALL> S<SMALL>ECURITIES</SMALL> E<SMALL>UROPE</SMALL> G<SMALL>MB</SMALL>H</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Wolfgang Koehler</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Wolfgang Koehler</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Risk Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Andreas Rieth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Andreas Rieth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">General Counsel &amp; Company Secretary</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL>
A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>)<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: MUFG S<SMALL>ECURITIES</SMALL> (E<SMALL>UROPE</SMALL>) N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Yashima Akanuma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Yashima Akanuma</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: I<SMALL>NTESA</SMALL> S<SMALL>ANPAOLO</SMALL> S.<SMALL>P</SMALL>.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Silvio Capone</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Silvio Capone</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Davide Vietri</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Davide Vietri</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: PNC C<SMALL>APITAL</SMALL> M<SMALL>ARKETS</SMALL> LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kevin Tooke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kevin Tooke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL>
A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>)<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>ITIGROUP</SMALL> G<SMALL>LOBAL</SMALL> M<SMALL>ARKETS</SMALL> I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">G<SMALL>OLDMAN</SMALL> S<SMALL>ACHS</SMALL> B<SMALL>ANK</SMALL> E<SMALL>UROPE</SMALL> SE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">M<SMALL>IZUHO</SMALL> S<SMALL>ECURITIES</SMALL> USA LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MUFG
S<SMALL>ECURITIES</SMALL> A<SMALL>MERICAS</SMALL> I<SMALL>NC</SMALL>. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I<SMALL>NTESA</SMALL> S<SMALL>ANPAOLO</SMALL> S.<SMALL>P</SMALL>.A. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PNC C<SMALL>APITAL</SMALL> M<SMALL>ARKETS</SMALL> LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">as Dollar
Underwriters </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: C<SMALL>ITIGROUP</SMALL> G<SMALL>LOBAL</SMALL> M<SMALL>ARKETS</SMALL> I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam D. Bordner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Adam D. Bordner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: G<SMALL>OLDMAN</SMALL> S<SMALL>ACHS</SMALL> B<SMALL>ANK</SMALL> E<SMALL>UROPE</SMALL> SE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jens Hofmann</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jens Hofmann</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ogven Sedgwick</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Ogven Sedgwick</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: M<SMALL>IZUHO</SMALL> S<SMALL>ECURITIES</SMALL> USA LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Seth Nadler</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Seth Nadler</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: MUFG S<SMALL>ECURITIES</SMALL> A<SMALL>MERICAS</SMALL> I<SMALL>NC</SMALL>.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Timothy Dilworth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Timothy Dilworth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL>
A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>)<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: I<SMALL>NTESA</SMALL> S<SMALL>ANPAOLO</SMALL> S.<SMALL>P</SMALL>.A.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Silvio Capone</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Silvio Capone</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Davide Vietri</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Davide Vietri</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By: PNC C<SMALL>APITAL</SMALL> M<SMALL>ARKETS</SMALL> LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Kevin Tooke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Kevin Tooke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>(<I>S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> U<SMALL>NDERWRITING</SMALL>
A<SMALL>GREEMENT</SMALL></I><SMALL></SMALL>)<I> </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCHEDULE I </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Part A </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Euro Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount&nbsp;of</B><br><B>2027 Euro Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BOFA SECURITIES EUROPE SA </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNP PARIBAS </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSBC BANK PLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. MORGAN AG </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS EUROPE AG </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS BANK EUROPE SE </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MUFG SECURITIES (EUROPE) N.V. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MIZUHO SECURITIES EUROPE GMBH </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTESA SANPAOLO S.P.A. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC CAPITAL MARKETS LLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&#128;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,100,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Euro Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount&nbsp;of</B><br><B>2030 Euro Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BOFA SECURITIES EUROPE SA </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNP PARIBAS </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSBC BANK PLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. MORGAN AG </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS EUROPE AG </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS BANK EUROPE SE </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MUFG SECURITIES (EUROPE) N.V. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MIZUHO SECURITIES EUROPE GMBH </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTESA SANPAOLO S.P.A. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC CAPITAL MARKETS LLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&#128;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,500,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Part B </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Dollar Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount&nbsp;of</B><br><B>2027 Dollar Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BOFA SECURITIES, INC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNP PARIBAS SECURITIES CORP. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSBC BANK PLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. MORGAN AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS INC. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS BANK EUROPE SE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MIZUHO SECURITIES USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MUFG SECURITIES AMERICAS INC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTESA SANPAOLO S.P.A. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC CAPITAL MARKETS LLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,000,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">Sch-I-1</FONT> </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Dollar Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal&nbsp;Amount&nbsp;of</B><br><B>2029 Dollar Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BOFA SECURITIES, INC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNP PARIBAS SECURITIES CORP. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HSBC BANK PLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. MORGAN AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">140,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CITIGROUP GLOBAL MARKETS INC. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS BANK EUROPE SE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MIZUHO SECURITIES USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MUFG SECURITIES AMERICAS INC.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">INTESA SANPAOLO S.P.A. </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC CAPITAL MARKETS LLC </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>1,000,000,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE II </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>ISSUER FREE WRITING PROSPECTUS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 433 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-260519</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>November&nbsp;2, 2021 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FREE
WRITING PROSPECTUS DATED NOVEMBER&nbsp;2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To the Prospectus dated October&nbsp;27, 2021, as supplemented by </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">the Preliminary Prospectus Supplement dated October&nbsp;27, 2021) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands II B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;1,100,000,000 3.750% Sustainability-Linked Senior Notes due 2027 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&#128;1,500,000,000 4.375% Sustainability-Linked Senior Notes due 2030 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Finance Netherlands III B.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000 4.750% Sustainability-Linked Senior Notes due 2027 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$1,000,000,000 5.125% Sustainability-Linked Senior Notes due 2029 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Payment of principal and interest unconditionally guaranteed by </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Teva Pharmaceutical Industries Limited </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">November&nbsp;2, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information in
this free writing prospectus dated November&nbsp;2, 2021 supplements the preliminary prospectus supplement dated October&nbsp;27, 2021 of Teva Pharmaceutical Finance Netherlands II B.V., Teva Pharmaceutical Finance Netherlands III B.V. and Teva
Pharmaceutical Industries Limited (the &#147;Preliminary Prospectus Supplement&#148;) and supersedes the information in the Preliminary Prospectus Supplement to the extent inconsistent with the information in the Preliminary Prospectus Supplement.
Unless otherwise indicated, terms used but not defined herein have the meaning assigned to such terms in the Preliminary Prospectus Supplement. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;1,100,000,000 3.750% Sustainability-Linked Senior Notes due 2027 (the &#147;<U>2027 Euro notes</U>&#148;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;1,500,000,000 4.375% Sustainability-Linked Senior Notes due 2030 (the &#147;<U>2030 Euro notes</U>&#148;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1,000,000,000 4.750% Sustainability-Linked Senior Notes due 2027 (the &#147;<U>2027 USD notes</U>&#148;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1,000,000,000 5.125% Sustainability-Linked Senior Notes due 2029 (the &#147;<U>2029 USD notes</U>&#148;)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issuer:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva Pharmaceutical Finance Netherlands II B.V. (&#147;<U>Teva Finance II</U>&#148;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva Finance II</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva Pharmaceutical Finance Netherlands III B.V. (&#147;<U>Teva Finance III</U>&#148;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva Finance III</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Guarantor:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva Pharmaceutical Industries Limited (&#147;<U>Teva</U>&#148;) <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Teva</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Issue Ratings*:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ba2 / <FONT STYLE="white-space:nowrap">BB-</FONT> (Moody&#146;s / S&amp;P)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ba2 / <FONT STYLE="white-space:nowrap">BB-</FONT> (Moody&#146;s / S&amp;P)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ba2 / <FONT STYLE="white-space:nowrap">BB-</FONT> (Moody&#146;s / S&amp;P)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Ba2 / <FONT STYLE="white-space:nowrap">BB-</FONT> (Moody&#146;s / S&amp;P)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Trade Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;2, 2021 <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;2, 2021 <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;2, 2021 <BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;2, 2021 <BR></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Settlement Date (T+5)**:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;9, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;9, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;9, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">November&nbsp;9, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Minimum Denomination:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;100,000 and whole multiples of &#128;1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;100,000 and whole multiples of &#128;1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$200,000 and whole multiples of $1,000 in excess thereof</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$200,000 and whole multiples of $1,000 in excess thereof</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Delivery:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Euroclear / Clearstream</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Euroclear / Clearstream</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Depository Trust Company</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Depository Trust Company</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Expected Listing / Trading:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Official List of Euronext Dublin / Global Exchange Market</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Official List of Euronext Dublin / Global Exchange Market</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sustainability-Linked Notes Structuring Agents:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Active Bookrunners:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities Europe SA;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities Europe SA;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas Securities Corp.;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities,
Inc.;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BNP Paribas Securities Corp.; BofA Securities, Inc.;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HSBC Bank plc;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan AG</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Passive Bookrunners:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Europe AG;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman
Sachs Bank Europe SE;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mizuho Securities Europe GmbH;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MUFG
Securities (Europe) N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Europe AG;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman
Sachs Bank Europe SE;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mizuho Securities Europe GmbH;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MUFG
Securities (Europe) N.V.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs
Bank Europe SE;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MUFG Securities
America Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs
Bank Europe SE;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MUFG Securities
America Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">Co-Managers:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intesa Sanpaolo S.p.A.;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PNC Capital Markets
LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intesa Sanpaolo S.p.A.;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PNC Capital Markets
LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intesa Sanpaolo S.p.A.;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PNC Capital Markets
LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intesa Sanpaolo S.p.A.;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">PNC Capital Markets
LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Offering:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.750% 2027 Euro notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.375% 2030 Euro notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.750% 2027 USD notes</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.125% 2029 USD notes</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Principal Amount:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;1,100,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#128;1,500,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1,000,000,000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$1,000,000,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Maturity Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9, 2027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9, 2030</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9, 2027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9, 2029</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Public Offering Price***:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">100.000% of principal amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">100.000% of principal amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">100.000% of principal amount</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">100.000% of principal amount</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interest Rate:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.750% semi-annual</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.375% semi-annual, subject to any adjustments upon the failure to achieve Sustainability Performance Targets.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.750% semi-annual</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.125% semi-annual, subject to any adjustments upon the failure to achieve Sustainability Performance Targets.</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interest Rate <FONT STYLE="white-space:nowrap">Step-up</FONT> for 2030 Euro notes and the 2029 USD notes:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and including May&nbsp;9, 2026 (the &#147;<U><FONT STYLE="white-space:nowrap">Step-up</FONT> Date</U>&#148;), the interest rate payable
on the 2030 Euro notes shall increase by:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(a) 0.125% per annum unless Teva has achieved the</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From and including the <FONT STYLE="white-space:nowrap">Step-up</FONT> Date, the interest rate payable on the 2029 USD notes shall increase
by:</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(a) 0.125% per annum unless Teva has achieved the Regulatory</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory Submissions Target as of December&nbsp;31, 2025 (the &#147;<U>Testing Date</U>&#148;);</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) 0.125% per annum unless Teva has achieved the Product Volume Target as of the Testing Date; and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(c) 0.125% per annum unless Teva has achieved the Emission Reduction Target as of the Testing Date.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Submissions Target as of the Testing Date;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)
0.125% per annum unless Teva has achieved the Product Volume Target as of the Testing Date; and</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(c) 0.125% per annum unless Teva has achieved the Emission
Reduction Target as of the Testing Date.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Premium Payment for 2027 Euro notes and the 2027 USD notes:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At maturity or upon earlier redemption of the 2027 Euro notes (but only if such redemption is on or after the
<FONT STYLE="white-space:nowrap">Step-up</FONT> Date), the following premiums shall be payable on the 2027 Euro notes:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) 0.150% of the principal amount repaid unless Teva has achieved the Regulatory Submissions Target as of the Testing Date;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) 0.150% of the principal amount repaid unless Teva has achieved the Product Volume Target as of the Testing Date; and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(c) 0.150% of the principal amount repaid unless Teva has achieved the Emission Reduction Target as of the Testing Date.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At maturity or upon earlier redemption of the 2027 USD notes (but only if such redemption is on or after the
<FONT STYLE="white-space:nowrap">Step-up</FONT> Date), the following premiums shall be payable on the 2027 USD notes:</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) 0.150% of the principal amount repaid unless Teva has achieved the Regulatory Submissions Target as of the Testing Date;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) 0.150% of the principal amount repaid unless Teva has achieved the Product Volume Target as of the Testing Date; and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(c) 0.150% of the principal amount repaid unless Teva has achieved the Emission Reduction Target as of the Testing Date.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interest Payment Dates:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9 and November&nbsp;9 of each year, beginning May&nbsp;9, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9 and November&nbsp;9 of each year, beginning May&nbsp;9, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9 and November&nbsp;9 of each year, beginning May&nbsp;9, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">May&nbsp;9 and November&nbsp;9 of each year, beginning May&nbsp;9, 2022</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Interest Record Dates:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Business Day immediately preceding the related Interest Payment Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The Business Day immediately preceding the related Interest Payment Date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The preceding May&nbsp;1 and November&nbsp;1, in each case whether or not a Business Day</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The preceding May&nbsp;1 and November&nbsp;1, in each case whether or not a Business Day</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Day Count Convention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30/360</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30/360</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30/360</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">30/360</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Yield to Maturity:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3.750%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.375%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">4.750%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5.125%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Benchmark:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">0.250% due February&nbsp;15, 2027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">0.000% due February&nbsp;15, 2030</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.375% due May&nbsp;15, 2027</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2.375% due May&nbsp;15, 2029</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Spread to Benchmark:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+421.7 basis points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+465.3 basis points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+353 basis points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+370 basis points</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Make-Whole Redemption:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">B plus 50 basis points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">B plus 50 basis points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Treasury plus 50 basis points</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Treasury plus 50 basis points</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Optional Redemption:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If Teva Finance II elects to redeem the 2027 Euro notes at any time on or after February&nbsp;9, 2027 (three months prior to the maturity date of the 2027 Euro notes), Teva Finance II may redeem the 2027 Euro notes, in whole or in
part, upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the 2027 Euro notes then outstanding to be redeemed plus accrued and unpaid interest thereon, if any, to,
but not including, the redemption date.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If Teva Finance II elects to redeem the 2030 Euro notes at any time on or after February&nbsp;9, 2030 (three months prior to the maturity date of the 2030 Euro notes), Teva Finance II may redeem the 2030 Euro notes, in whole or in
part, upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the 2030 Euro notes then outstanding to be redeemed plus accrued and unpaid interest thereon, if any, to,
but not including, the redemption date.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If Teva Finance III elects to redeem the 2027 Dollar notes at any time on or after February&nbsp;9, 2027 (three months prior to the maturity date of the 2027 Dollar notes), Teva Finance II may redeem the 2027 Dollar notes, in whole
or in part, upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the 2027 Dollar notes then outstanding to be redeemed plus accrued and unpaid interest thereon, if
any, to, but not including, the redemption date.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If Teva Finance III elects to redeem the 2029 Dollar notes at any time on or after February&nbsp;9, 2029 (three months prior to the maturity date of the 2029 Dollar notes), Teva Finance II may redeem the 2029 Dollar notes, in whole
or in part, upon at least 10 days&#146;, but not more than 60 days&#146;, prior notice at a redemption price equal to 100% of the principal amount of the 2029 Dollar notes then outstanding to be redeemed plus accrued and unpaid interest thereon, if
any, to, but not including, the redemption date.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">ISIN numbers:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XS2406607098</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XS2406607171</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">US88167AAP66</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">US88167AAQ40</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Common Codes (for Euro notes) / CUSIP numbers (for Dollar notes):</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">240660709</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">240660717</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">88167AAP6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">88167AAQ4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Time of execution</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">19:29 (UK time)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">19:29 (UK time)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">19:25 (UK time)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">19:25 (UK time)</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or
withdrawal at any time. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">It is expected that delivery of the notes will be made to investors on or about November&nbsp;9, 2021, which
will be the fifth business day following the date of pricing of the notes (such settlement being referred to as &#147;T+5&#148;). Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Securities Exchange Act of 1934, as amended, trades in
the secondary market generally are required to settle in two business days, unless the parties to the trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes prior to the delivery of the notes will be required, by virtue
of the fact that the notes initially will settle in T+5, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement and should consult their own advisors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">***</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In each case, plus accrued interest from November&nbsp;9, 2021, if settlement occurs after that date.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Amendments to the Preliminary Prospectus Supplement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In addition to the pricing information above, this free writing prospectus amends and updates certain sections of the Preliminary Prospectus Supplement, as
described below. Additional conforming changes are made to the Preliminary Prospectus Supplement to reflect the changes described herein. Section references in the amended sections below refer to the sections of the Preliminary Prospectus Supplement
as amended and supplemented by this free writing prospectus and all footnotes to the tables in this supplement not included herein remain the same as those in the Preliminary Prospectus Supplement. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Upsize of the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate principal amount of the offering has been increased to approximately $5,000.0&nbsp;million (equivalent). After deducting the underwriters&#146;
discounts and estimated offering expenses, Teva intends to use the net proceeds of this offering (i)&nbsp;to fund the Tender Offer for a maximum combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $3.5&nbsp;billion
(as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith, (iii)&nbsp;to fund the repayment of outstanding debt upon maturity, tender offer or earlier redemption and (iv)&nbsp;to the extent of any
remaining proceeds, for general corporate purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following paragraph is added to the end of the section entitled &#147;Recent Developments&#148; on page <FONT STYLE="white-space:nowrap">S-3</FONT> of
the Preliminary Prospectus Supplement: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed in note 10 to Teva&#146;s financial statements for the quarter ended September&nbsp;30,
2021 included in its Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> filed on October&nbsp;27, 2021, on April&nbsp;19, 2021, a bench trial in California (The People of the State of California, acting by and through Santa Clara
County Counsel James R. Williams, et. al. v. Purdue Pharma L.P., et. al.) commenced with Teva and other defendants focused on the marketing of branded opioids. On November&nbsp;1, 2021, the Superior Court of Orange County, California, issued a
decision finding that Teva did not cause a public nuisance in Orange County, Los Angeles County, Santa Clara County and the City of Oakland, and that Teva did not make any false or misleading statements in connection with marketing prescription
opioids in California. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Notes and the Guarantees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The definitions of &#147;Remaining Scheduled Payments&#148; on pages <FONT STYLE="white-space:nowrap">S-35</FONT> and
<FONT STYLE="white-space:nowrap">S-53</FONT> of the Preliminary Prospectus Supplement are amended by adding the <U>underlined</U> wording below. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Remaining Scheduled Payments&#148; means, with respect to each note to be redeemed, the remaining scheduled payments of principal of and interest on
such note as if redeemed on the applicable Par Call Date<U>, determined at the interest rate to be applicable on such redemption date</U>. If the applicable redemption date is not an interest payment date with respect to such note, the amount of the
next succeeding scheduled interest payment on such note will be reduced by the amount of interest accrued on such note to such redemption date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional conforming changes are
made to the Preliminary Prospectus Supplement to reflect the changes described herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Teva Finance II, Teva Finance III and Teva have filed a registration statement (including a prospectus and a preliminary prospectus supplement) with the
Securities and Exchange Commission (the &#147;</I><B><I>SEC</I></B><I>&#148;) for the offering to which this communication relates. Before you invest, you should read the prospectus and the preliminary prospectus supplement in that registration
statement and other documents Teva and the Issuers have filed with the SEC for more complete information about Teva and the Issuers and this offering. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You may get these documents for free by visiting EDGAR on the SEC website at www.sec.report. Alternatively, Teva, the Issuers, any underwriter or any
dealer participating in the offering will arrange to send you the prospectus if you request it by contacting BofA Securities Europe SA, 51 rue La Bo&eacute;tie, 75008 Paris, France, Attention: High Yield Syndicate Desk (Tel: +3318770 0000, email:
levfin_hy_paris@bofa.com); BofA Securities, Inc., One Bryant Park, New York, New York 10036, United States of America, Attention: Legal Department (fax: +1 212 901 7897); BNP Paribas Securities Corp., 787 Seventh Avenue, New York, New York 10019,
USA, Attention: Syndicate Desk (email: <U>new.york.syndicate@bnpparibas.com</U>); BNP Paribas, 16, boulevard des Italiens, 75009 Paris, France, Attention: Fixed Income Syndicate (email: dl.syndsupportbonds@bnpparibas.com); HSBC Bank plc, 8 Canada
Square, London E14 5HQ, United Kingdom, Attention: Transaction Management EMEA Debt Capital Markets (Fax: +44 20 7992 4973); or J.P. Morgan AG, Taunustor 1 (TaunusTurm), 60310 Frankfurt am Main, Germany (Email: emea_syndicate@jpmorgan.com),
Attention: Head of International Syndicate. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The notes are not intended to be offered, sold or otherwise made available to and should not be
offered, sold or otherwise made available to any retail investor in the European Economic Area (&#147;</I><B><I>EEA</I></B><I>&#148;). For these purposes, a retail investor means a person who is one (or more) of: (i)&nbsp;a retail client as defined
in point (11)&nbsp;of Article 4(1) of Directive 2014/65/EU (as amended, &#147;</I><B><I>MiFID II</I></B><I>&#148;); or (ii)&nbsp;a customer within the meaning of Directive 2016/97/EU (as amended, the &#147;</I><B><I>Insurance Distribution
Directive</I></B><I>&#148;), where that customer would not qualify as a professional client as defined in point (10)&nbsp;of Article 4(1) of MiFID II; or (iii)&nbsp;not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129.
Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the &#147;</I><B><I>PRIIPs Regulation</I></B><I>&#148;) for offering or selling the notes or otherwise making them available to retail investors in the
EEA has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Professional investors and eligible counterparties only target market: Solely for the purposes of the manufacturers&#146; product approval process, the
target market assessment in respect of the debt securities has led to the conclusion that: (i)&nbsp;the target market for the debt securities is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook
(&#147;</I><B><I>COBS</I></B><I>&#148;), and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the EUWA (&#147;</I><B><I>UK MiFIR</I></B><I>&#148;); and (ii)&nbsp;all channels for
distribution of the debt securities to eligible counterparties and professional clients are appropriate. A distributor should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to the FCA
Handbook Product Intervention and Product Governance Sourcebook (the &#147;</I><B><I>UK MiFIR Product Governance Rules</I></B><I>&#148;) is responsible for undertaking its own target market assessment in respect of the debt securities (by either
adopting or refining the manufacturers&#146; target market assessment) and determining appropriate distribution channels. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Consequently, no key
information document required by Regulation (EU) No 1286/2014 as it forms part of UK domestic law by virtue of the EUWA (the &#147;UK PRIIPs Regulation&#148;) for offering or selling the notes or otherwise making them available to retail investors
in the UK has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Promotion of the notes in the United Kingdom is restricted by the Financial Services and Markets Act 2000 (the &#147;</I><B><I>FSMA</I></B><I>&#148;), and
accordingly, the notes are not being promoted to the general public in the United Kingdom. This announcement is for distribution only to, and is only directed at, persons who (i)&nbsp;persons who are outside the United Kingdom or
(ii)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the &#147;</I><B><I>Order</I></B><I>&#148;), (iii) high net worth entities, and other persons to whom
they may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order or (iv)&nbsp;persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with
the issue or sale of any notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as &#147;</I><B><I>relevant persons</I></B><I>&#148;). The notes will only be available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise acquire such notes will be engaged in only with, relevant persons. This announcement is directed only at relevant persons and must not be acted on or relied on by anyone who is not a
relevant person. </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Advertisement: The final prospectus, when published, will be available on <U> </U></I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>https://live.euronext.com/en/markets/dublin/bonds/list</U> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Relevant stabilization regulations including FCA/ICMA will apply. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The notes have not, may not and will not be offered, sold or delivered in the Netherlands, other than to qualified investors (as defined in Regulation (EU)
2017/1129). </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The notes have not, may not and will not be offered, sold or delivered in Israel, other than to persons who qualify as one of the
types of investors listed in the First Addendum to the Israeli Securities Law, subject to and in accordance with the requirements set forth in the First Addendum to the Israeli Securities Law. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it
is unlawful to make such offer or solicitation in such jurisdiction. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO
THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d599039dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Proceeds to Repay Existing Debt </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TEL AVIV&#151;(BUSINESS WIRE)&#151;<B>November</B><B></B><B>&nbsp;2, 2021</B>&#151; Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA)
(&#147;<B>Teva</B>&#148;) announced today that it successfully upsized and priced approximately $5,000,000,000 (equivalent) of its debut sustainability-linked senior notes (the &#147;<B>Notes</B>&#148;). The principal amount of the offering was
increased from the previously announced offering size of $4,000,000,000 (equivalent). Teva expects to use the net proceeds from the offerings to (i)&nbsp;fund the announced tender offer to purchase, for cash, its 1.250% Senior Notes due 2023, its
2.800% Senior Notes due 2023, its 3.250% Senior Notes due 2022, its 2.950% Senior Notes due 2022, its 1.125% Senior Notes due 2024 and its 6.000% Senior Notes due 2024 for a maximum combined aggregate purchase price (exclusive of accrued and unpaid
interest) of up to $3,500,000,000 (as it may be amended prior to expiration thereof), (ii) to pay fees and expenses in connection therewith, (iii)&nbsp;to fund the repayment of outstanding debt upon maturity, tender offer or earlier redemption and
(iv)&nbsp;to the extent of any remaining proceeds, for general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This is the largest-ever offering of Sustainability-Linked Notes, and
the first-ever issued by a generic medicine company. The transaction marks Teva&#146;s debut into Sustainable Finance and is tied to targets that include improving access to medicines in <FONT STYLE="white-space:nowrap">low-</FONT> and middle-income
countries (LMICs) and reducing greenhouse gas (GHG) emissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes consist of (i)&nbsp;Teva Pharmaceutical Finance Netherlands II B.V.&#146;s
(&#147;<B>Teva Finance II</B>&#148;) &#128;1,100,000,000 aggregate principal amount of 3.750% <FONT STYLE="white-space:nowrap">EUR-denominated</FONT> Sustainability-Linked Senior Notes maturing in 2027, (ii) Teva Finance II&#146;s
&#128;1,500,000,000 aggregate principal amount of 4.375% <FONT STYLE="white-space:nowrap">EUR-denominated</FONT> Sustainability-Linked Senior Notes maturing in 2030, (iii) Teva Pharmaceutical Finance Netherlands III B.V.&#146;s (&#147;<B>Teva
Finance III</B>&#148; and, together with Teva Finance II, the &#147;<B>Issuers</B>&#148;) $1,000,000,000 aggregate principal amount of 4.750% <FONT STYLE="white-space:nowrap">USD-denominated</FONT> Sustainability-Linked Senior Notes maturing in 2027
and (iv)&nbsp;Teva Finance III&#146;s $1,000,000,000 aggregate principal amount of 5.125% <FONT STYLE="white-space:nowrap">USD-denominated</FONT> Sustainability-Linked Senior Notes maturing in 2029. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The settlement of the Notes is expected to occur on or about November&nbsp;9, 2021, subject to customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes will be unsecured senior obligations of the Issuers and will be unconditionally guaranteed on a senior basis by Teva. The offering and sale of the
Notes were made pursuant to our effective automatic shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including our base prospectus, filed with the Securities and Exchange Commission (the &#147;<B>SEC</B>&#148;) on
October&nbsp;27, 2021. The offering of these Notes were made only by means of a prospectus supplement and accompanying base prospectus, which have been filed with the SEC. Before you invest, you should read the prospectus supplement and accompanying
prospectus along with other documents that Teva has filed with the SEC for more complete information about Teva and this offering. These documents are available at no charge by visiting EDGAR on the SEC website at http://www.sec.gov. Alternatively,
a copy of the prospectus supplement and accompanying base prospectus related to this offering may be obtained, when available, by contacting Sanat Babu of the BofA Securities Group SA team (email: sanat.babu@bofa.com). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any
securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Teva </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) has been developing and producing medicines to improve people&#146;s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic
area. Around 200&nbsp;million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have
significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Note Regarding
Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995, which are based on management&#146;s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ
significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: completion of the offering of senior notes and tender offer for certain
outstanding notes; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; our inability to
raise debt or borrow funds in amounts or on terms that are favorable to us; and other factors discussed in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December</I><I></I><I>&nbsp;31, 2020, including the
sections thereof captioned &#147;Risk Factors&#148; and &#147;Forward Looking Statements</I>,<I>&#148; and in our subsequent quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other filings with the SEC, which are available
at www.sec.gov. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new
information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. No assurance can be given that the transactions described herein will be consummated or as to the ultimate terms of any such
transactions.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It may be unlawful to distribute this press release in certain jurisdictions. This press release is not for distribution in Canada,
Japan or Australia. The information in this press release does not constitute an offer of securities for sale in Canada, Japan or Australia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes are not intended to be offered, sold or otherwise made available to and should not be offered,
sold or otherwise made available to any retail investor in the European Economic Area (&#147;<B>EEA</B>&#148;). For these purposes, a retail investor means a person who is one (or more) of: (i)&nbsp;a retail client as defined in point (11)&nbsp;of
Article 4(1) of Directive 2014/65/EU (as amended, &#147;<B>MiFID II</B>&#148;); or (ii)&nbsp;a customer within the meaning of Directive 2016/97/EU (as amended, the &#147;<B>Insurance Distribution Directive</B>&#148;), where that customer would not
qualify as a professional client as defined in point (10)&nbsp;of Article 4(1) of MiFID II; or (iii)&nbsp;not a qualified investor as defined in Article 2 of Regulation (EU) 2017/1129. Consequently no key information document required by Regulation
(EU) No 1286/2014 (as amended, the &#147;<B>PRIIPs Regulation</B>&#148;) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise
making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Promotion of the Notes in the United Kingdom is
restricted by the Financial Services and Markets Act 2000 (the &#147;<B>FSMA</B>&#148;), and accordingly, the Notes are not being promoted to the general public in the United Kingdom. This announcement is for distribution only to, and is only
directed at, persons who (i)&nbsp;persons who are outside the United Kingdom or (ii)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
&#147;<B>Order</B>&#148;), (iii) high net worth entities, and other persons to whom they may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order or (iv)&nbsp;persons to whom an invitation or inducement to engage in
investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as
&#147;<B>relevant persons</B>&#148;). The Notes will only be available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Notes will be engaged in only with, relevant persons. This announcement is directed
only at relevant persons and must not be acted on or relied on by anyone who is not a relevant person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The notes have not, may not and will not be
offered, sold or delivered in the Netherlands, other than to qualified investors (as defined in Regulation (EU) 2017/1129). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notes have not, may not
and will not be offered, sold or delivered in Israel, other than to persons who qualify as one of the types of investors listed in the First Addendum to the Israeli Securities Law, subject to and in accordance with the requirements set forth in the
First Addendum to the Israeli Securities Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contacts </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IR Contacts:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Kevin C. Mannix</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(215) <FONT STYLE="white-space:nowrap">591-8912</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Yael Ashman</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Israel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">972 (3) <FONT STYLE="white-space:nowrap">914-8262</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">PR Contacts:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Kelley Dougherty</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(973) <FONT STYLE="white-space:nowrap">832-2810</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Yonatan Beker</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">United States</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(973) <FONT STYLE="white-space:nowrap">264-7378</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Eden Klein</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Israel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">972 (50) <FONT STYLE="white-space:nowrap">401-9959</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>teva-20211102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/4/2021 10:57:09 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:teva="http://www.tevapharm.com/20211102"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.tevapharm.com/20211102"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20211102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="teva-20211102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>teva-20211102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/4/2021 10:57:09 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>teva-20211102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 11/4/2021 10:57:09 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="teva-20211102.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d599039d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="teva-20211102.xsd" xlink:type="simple"/>
    <context id="duration_2021-11-02_to_2021-11-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000818686</identifier>
        </entity>
        <period>
            <startDate>2021-11-02</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2021-11-02_to_2021-11-02"
      id="Hidden_dei_EntityRegistrantName">TEVA PHARMACEUTICAL INDUSTRIES LTD</dei:EntityRegistrantName>
    <dei:EntityAddressCountry
      contextRef="duration_2021-11-02_to_2021-11-02"
      id="Hidden_dei_EntityAddressCountry">IL</dei:EntityAddressCountry>
    <dei:EntityTaxIdentificationNumber
      contextRef="duration_2021-11-02_to_2021-11-02"
      id="Hidden_dei_EntityTaxIdentificationNumber">00-0000000</dei:EntityTaxIdentificationNumber>
    <dei:AmendmentFlag contextRef="duration_2021-11-02_to_2021-11-02">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-11-02_to_2021-11-02"
      id="Hidden_dei_EntityCentralIndexKey">0000818686</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-11-02_to_2021-11-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-11-02_to_2021-11-02">2021-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-11-02_to_2021-11-02">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-11-02_to_2021-11-02">001-16174</dei:EntityFileNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-11-02_to_2021-11-02">124 Dvora Hanevi&#x2019;a Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-11-02_to_2021-11-02">Tel Aviv</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-11-02_to_2021-11-02">6944020</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-11-02_to_2021-11-02">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-11-02_to_2021-11-02">3-914-8213</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-11-02_to_2021-11-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-11-02_to_2021-11-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-11-02_to_2021-11-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-11-02_to_2021-11-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-11-02_to_2021-11-02">American Depositary Shares, each representing one Ordinary Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-11-02_to_2021-11-02">TEVA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-11-02_to_2021-11-02">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-11-02_to_2021-11-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140429347374552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TEVA PHARMACEUTICAL INDUSTRIES LTD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000818686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  02,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-16174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">124 Dvora Hanevi&#8217;a Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Tel Aviv<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6944020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3-914-8213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">American Depositary Shares, each representing one Ordinary Share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TEVA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MIR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%
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M>FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@R*2*Y U+2X<L-03&IAJ
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " "-A613F5R<(Q &  "<)P  $P
M            @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M (V%9%-FNXC=400  &H0   8              " @0X(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " "-A613GZ ;\+$"  #B#   #0
M            @ &5#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (V%9%.7
MBKL<P    !,"   +              "  7$/  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( (V%9%,<.&7J/P$  #P"   /              "  5H0  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " "-A613)!Z;HJT   #X 0  &@
M        @ '&$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " "-A61399!YDAD!  #/ P  $P              @ &K$@  6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #U$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d599039d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d599039d8k.htm">d599039d8k.htm</File>
    <File>d599039dex11.htm</File>
    <File>d599039dex991.htm</File>
    <File>teva-20211102.xsd</File>
    <File>teva-20211102_lab.xml</File>
    <File>teva-20211102_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d599039d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d599039d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "teva-20211102_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "teva-20211102_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "teva-20211102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "teva",
   "nsuri": "http://www.tevapharm.com/20211102",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d599039d8k.htm",
      "contextRef": "duration_2021-11-02_to_2021-11-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d599039d8k.htm",
      "contextRef": "duration_2021-11-02_to_2021-11-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tevapharm.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-320242-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-320242-xbrl.zip
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M.MYYQA%U)7L2<CHPI:!NSW/8[">60[.5#CLCHUH]M4Z/3X]7X:LL285@(R;
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MG^@A5JS4NNBD25R"LS9\*X6Y J?Y?M@KV,LP7]&:A@.S6W4I>R5A$W,H=FQ
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MDYU=E-S#UUYG%@T'!H0I* Y?@QY):([,H&KK0"3O3NU]*%!G:5R<2-A[UKU
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M&XY%_.2<#<6F]$<WG8H<1SS_5@14)?,EAV''[%KN]_;Z-0 9B[:^A.&. %G
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MABIFI)-=+(DRM4ZIXET:E>79O93*$.FXX;:8/7$7Z=F0:QT>*X:*A\6J+:%
MS3F2O<57"7D3#*0Q0W,IOK'_,#HM%]B>OLHL;F/3Q!VXJ (L'N(Z:]Q4T%:#
MBD58N-S0=96!^RYLW'/'7J>3U.[]][K<B;FYT@R(C:;'6\)7$(/8Q]B90*&A
MV!&N-\>OU[XO[?U0Q/>M+@S,5N=:$8 JN@<HY:SO*MF1K1V;6*Y[F\+"BPM;
MKW&=;C>4A5#RU)5<*5)*I-5U2LBFC@4K&T-6%5E2>0*W1^"<6FXM&Q^4H0NF
M7)8+[$?WW%#%(:,\.W$!>1P[P4/D^2X].4]_>'(V1L?I=G14YJC9>W7FFIS\
MIA$'R%! _W^V]71;BX</A^\.WV"R/\'S_T*IB:0X<PR='<9OOU@926\H 0[#
M*/N[>T_N/WKVP&/_@<$HK\56?3@52>4NSA;-0L+_V#]7HTG#)&&QBVDRQE*F
MRFXDWO61Y]=E,<^\DWEX>=# [6ZL'L.+KS11ISCVZ57"^*_*Z8$M$;B4&_15
M8F^>LZ%5[4=K &KX8)V*!\S1E"=IHXI%_!<16L0Z3T<9-H@%M8[%LPD>^JKD
M^S5,$I2Z5NLPGT-$6"_-X2)*1U"O]%*1T]O#=LO-Y06%G\X9ORKWN4%PKD92
M!94-**$ S )SL& 18JI(\UHIPS;2JZ^ZZSJ15#7M,ODT%"=8-$J+^839%S-N
M!^VW/K5["S:=*3RM6H4"<04<*,96LJ@W82(%9/K7RJZY H6#61MVQ;3#:ABA
M8H^&!;(EQ]Q)%UP&8HI1@J<.2G?PH*U:Z37.W/8J><2_ 8*(;X0@T&?811'7
MLZ1N@"UW\.66VM_+F3=%N,":?>8;LJDZ>6\O PV_W,5"L?[BCO'0Z/(LM&W-
MK7%GJ G\[7'1UIQ9I-X".0H?#:8]W7E.VCYZUW7KWX.[Q$S)4EQ-&'? ,36]
MM 'R8&=_Y\EGC9/S^B#Z%38#_2#4D9;HY)"0BO%T!=HG0$!'Y:(:I_B>QR2Q
M?BY[=_BYD^INU 19^;4?MDB_P'/#M'C8KSY^P@2X; 2WNF5\P'[3O"]M?(1>
MM$D!TY0Z96?PY9NQ/E82T.9%*/K%-V*&7-EJ^'Z]7<]^>+ONFAWGW[#AX&IZ
M2(?:>26#+LQ0-GRU=OJ,\>_)_OI6TJBE6,@TKV!]A5^^(>OK#LB0ZYEA:')=
MC]1[K*9;<3ZM9301H-C:?.N*YM.5V%:G]=1!Q^MS+M"SKG2>W[Y,[P&5Z0FF
MKHGI:<NFLP\0%^Q9+8.& _7LEM74C8[=C.IG=3Y ?H1C>[^M5!(J)<\Q:&EW
M\EF1+P/E!+&J!Y*:(\F6CU6HDN=U;=/E9HH.T7XY+@E@S^IFDTZQMH;8+$']
M>.NGKA""FH!_6JL3A/72<"!M(:(572$0!YG /6W8ACFC/AF4(RNCKV\E&J"(
M<YBE 02W_8GRDCK[**P*?\$(:KMH2(; 2SO18>N1<8JY'YR+AV-3CH*UN.'
M7YWU&6NONKI=M-4RCJ]WKQ<=*76K>4=9A+X:<3Y!QPM6LB9F6IPP2!\UTD/0
M>5X5XCC-%=4+PG**?@9$%2)  1QX8N&+T?=UXQB=5E-X,_A^P_/[NS\,EHWF
M5Y:J=-US#S*H'"7]L/)EDDO]7)OA0/B]4M+X6F%9)V%<6(Q'=2_E!D-YLM0
M<])%E>Z)-0L[=P65BNCA_D.<M]"_T3-L!"K\,A=84)O-=NT] 5[@& 8[E*],
MG6(.C($F>).@YS#/RPOE@W-:[PX'W;UW7[A,E0!2B])(, 3'XMNJ^J<JD)1^
M\(+(Y"U9^V0W &&TU; 7>+LG\\EJ2FGUDJL,0@U78+P8#BS 4NIP=)Y) 7$K
M#<NP-*J*S! ]:)Q2;C2<DF3Y<?VKJD##-*:+4P6&J+>I?U,T$(-N\AO>4[<+
MI_Y".K'_X@W&]#D<P-$56<WZGY,&15KAN)Q3<W%>S@N[99[0MMF+/!?<MA;\
M#W_1:40= I%P[H4+(8]Z61S!?\;XGX>XS+U'F%&FA*62-HCLAL!;F$]G-LB2
M+N3P5GNB\H#K4@MZ>MPNH\(5:O9A+6TE>%/EE-7:1M+6^:;H3/=!E\VV-K><
MHA6P1/&,C=,G@DPLZ(;T,WS^7/",J)*@-CAD44D@%):ULC#X>W;\17[%+]>6
M9?7G J3$U#.W+%N'&K+YFR?Z@@V89]9:P(L:A$OAG@F^CS2Q$$PX('-]>;"0
MG,,EL;4!*@&SO6_::IB9S7"QGQ3;[N9LK3M*TYEP7B)EQ&K+3537<\6*%,3,
MN54$8+K="[Y8YY%B"LQUS]1[3^^B<Z"$<;"H+7Z0-;6M@!)^G:6%EB/2N3-!
MAN0F%@Y25S8U;4MC/!@LU:8)]#-0Z1^EQ1",<B%)SW(XM1,27%#-(4[$GR/9
M.-P"W!9L/>--TG%.B#F<D(RY>I:Q8EDH=\#*&SN*4D* G#GWRJQ/T[1A7'0X
M)(*PY(!C(HVCYQV76%DC^B)K!J4U+TJ:[E.]VJJ3F5- =7KPP)(#8=7)@@ C
M0:QYN"I%PM?N2(KTUKJ-CS76R6D"1[4H<E3M$ QSQ/V-!3]?731V(J*6A *^
M83C7VJY76%$5YQ>_]P*>R-RT5.Q>A3]]5%-XRH+1:-80*_EL=2&*5R[,!3JF
M\7&JG(B/VBY]@7]UEHJAS]@(QGWKD;F%5FW0(9$QB7+S#O$/_HD/P^LN)[5>
M-8T&[$'$]SW%(2YD"*."2,AUBUJX3U5% ]^$W4>]UV#;4\M *+;ULKI=41?2
MU$B!ED-:]3Z[S-5E[9UB+-X$LG#P*9\GN;T\>?Z=6B-JBP+*\,+40:I&7"NH
MAJI TEK>-T4+$S2$)EHZD$8MG;A:'6X[R"!UX> -@H2"D-"9*BGBY%9ED8TC
M;$9'Y3#?L=MC[X?;HT=T7$I4'"@MK(-/*'*6RQX6M')5/>9L=V3LQ_]1O.J3
M-JR[&)_" #I>+=&80VY]I9#.4OS,I-OSI2=V3;\(RP.24ZMG1#Y=FU\/!Z&G
M/#@RF0^#FMH3HM\LPS/2#-1/RV(>N/?X(8VSBCE&+A LN4-6+=.&3/?X$U!4
MOB09@'\,,/DXRM,3K?1/I)@N$ISV.Y 'EX*V-"$E5CDQM/$A(MO%?R@$SGD!
M-R-GD]!_*(Y>@1)011_&OZ7%O[,T>O_^$UDB8A_BD4>".(UF7#(F!/54_6Y<
MSI<K[$'4;ZKL! 5;OA01%MQ]#4QB63LB'WK>,N>=$%D6C 5*@WVE/J:U$OR-
MZJ1]^T<YW8X.IU0-2<WZ4$EW7'I"I6W;=%U7JH/F'YL@1%2.QU@Z2=Q,.H]@
M7:E&^PHT:F'M340X#86M0!>I90>2XTBCJV+$ENQM:II>2F=):C7I/*+-W4CY
M5LF58KK(- (7(_I\3LCELM1Q5HT7,PQ%C77YF.#F$..ZP"X#"N6'S2K<9E)\
MLSI/$[:Z;8% G$VCF*#+:;JT[EA HM0"Y4:;8IP)@4U$YLBQ,=B\+%?=4\5O
MZ?A8THGM=J9'W <ZOD&0CMCK(QW+BFO;,5#*G='!0O4%&GCI>6J]#P;XBXH@
M_HGT*.9PW7X,%VX%#X2QW 7K\X1XJ2IK7\E+A9%&(3[*.R&P)$($)N0P*8%2
MF2U)YHW[[BG[DOT]LAJ@86).6<V8XV8F\?EZ/+>/Y6XY>)2FI;9BJML!$!E/
MD; =\YB'8E-XZ-FNE'<]RWYKDQXDX;6V3]OFOZSQL7-=18>H?OO*CF\,L=C:
MB,NQN T*T8VE)RDD&,2KKUN%W\3Q]Y[LK[![*?(\=?F>E@"*WDBQ(VE027I.
M4!ZX*F1#(9TPTV(Y@5E62E#<O)R@"#UEI/4*C/AR$B-R!4;L"0D.9/E!S:Q6
M-(;A3^X.-=4?AEM:B,NPCV\PQ($ITF F@,)!&^".D.P2!F[(5V\1:^F&9BV7
MSL&X(1^V2+D.OV2LD;6S2K$EAO=5;E14-90ZJGI-C$\Q/ZQ/*:5N;(P;2G#<
MQJ&* H-ZV"@VEW03G+5J/D<Q359)0.KC0PYK?LCJV= EP1@Z%B\2K@K^B]F3
M;:%V[&L3"B358'Y."8ZS45:&29PSGC=WQV 41MY34N0[]HCL__"(;$R=.=V.
MWBQ4$$)H%773M22A,"?DWAFU]=7BC9+W1+Y9_.-V1%NL R5:70OK->LG':B%
MMY,*^A(/XO[ F#1XA!5KB6#%!O]83$YLD#//E=P*3(S<$$Z;DVM'NQPI6^ZM
MV.Y=4+JS;6Q6=Y,9""V*O7,*66R,^V[WTV6(-EY!F^;?SI)[,HJD0:J(F)Z>
M++H\U;\MO9?!N*P2]AE)G/1JQA8^8(7Y5@;V6#E0CYG$-B>K;92&$MON@-OO
MC^WH__T,ZZG.T\G_=Q>N\!G9S=Q=GN-*TB(\B*]_Y"AWIE\!Z]_L4/_"KI-/
M,I XSY4%:A*90J2K_>IVM?RM'UH.;$[M!F5C*7IGJ#:^^Q;\,]L<V!'$:@*(
MTMAT >0H[52X6\R]9!2$/(5509><2T[D5DGMQ$F_%GW;ZEW&!'Z.&55\-\B8
MT9T%2;B-R>OG]@:,K6;%M#+Z8*:&U-!_TAM3.IO;5K8"_EM0R_ARNBUM@[E:
M _XQ'-CM -E.&#6VB<"=.;E=)T52+,A4I]^BX-5Z0E89*2LCHD$HU=N]>3-L
M%L@<'XS?ZS:,C"[1+](Q=S;>,'*-8[QT+\GOV&IZ\,-JVMB5*K9!!^.NT5:G
MMY8*X2;G*:W$20E$SN5+/,6M=66;K<:8VDKN8SYEY=/MEMS16 "U4JNM@-'Q
M_I[,$W;LJLXPE E"&BY"GB9%,I&:+[<0R%D+W2_E(C&JNF\N*D'/^25VRJ^3
M?H*#%:4$H%C]LJ_R2&-4,C_AF9"_:V(!;@=R8T5GYU@*"M"BO,#YREJ8BPFW
MM)FBE9142[<Y\4""EB5\28I4.<R1-7ZN3HD]TY**NVFB/%%HFRNMD/@R*U'3
MXW68R8+P9^4Y^2I-:+O&I*1362P.;-0%M&JL7GO)5]AK4S7H!^^Q,&(XF -C
M/JF2^>D=T+'*NZ88S[E5,!*;.!_3.6N]06=N6E#TCHBQ"$NYHI5=IH8:ES-6
MEUB#S@K@"@W9;F,&)Q8E.MP.UJ29&B9T:(80?&-R+>BJVV"[=9FO9<8V'I[L
M+3?DIB.A4('E@$%H];2B4DV5_JPBN1T'8:#=*1V.4FFJ!.P1NC? FJG4^2ZL
MN-*%K"LRTDW'0#O3DPI8DC'6$ F?)S1H=HY3'6_3Z,"#MF6&@VDRMI",WAR_
M[H>2=E#9;YV3U+1GTJ,-8ZU9Q:8;S!)3?)6SSD5NX'1^T(S+G-/>1>_%.Z::
MN07:"QQ9CWW@QQQ\!\FH@D]6B)6 WS=H/WDJM13< UHZ0*O^SVQ3V>45'#T%
MD37)E0=(E7Z0M4YM!N8I-39/%B#64 V/0PUP%:COXZU'VR3R5W41I[[@V#K\
M_M[N(_*07;:I^,=RA]\P[=%-K? <N!E"..59HDL;-#<"8S++K]V+W,M &RV6
MV&B<8%:QQ;C38/S?;H-QJ]5 X+SI6W@]$>U=]3DA9W'CM)HW%7PCIP,\Z8L<
M/1*(9%1/SM/J'@B'DO="M#>G8SDW7XG.,Z!]4B?FJFDSR0>NQ]:6F=IIIS41
M-<C,097+HU,P#(U"A!J5L1<M-0,K<I(LCTF[P':')1=8Z/&#.\1R#J._5$BB
M&]A)YCUU(K2,]35;XB#]PSVIQ0*FPG>\!B5G]I>-(J7AP#U7+<%'954(=KO4
M7$U!O5**( D_&M&\H!L!4*"0D\AC!TTAL/Z=Z-?R NL-8AZ3U4)8-E 7W4G:
M\-X=1!<0>V!JTGL99B#0H,IZF6"3\>UMEGBZM[W47=E;PD2U@[M^BH-+]8QJ
MLY!19P%6%LUND*^@0O]-S2TU2Z5H=AQC(XUKXV#7'NT!XOZI7TEC+ZE)F.XE
M"88J]9.$_R.^UFZ+"(I\;\?BLJ)$%SWBHY4C]G<?WHF.)#9MMI-,3-)+L#ME
MK,(.R-A+Y(X+/UT%68^UJPC>XG6("A&%P]@%1)<N6B]S^8Y])P]_^$XVIC8U
M:ZI-'MZPE$&*VF0X;;?>I(!Z?FA._Z=H3MTG_OWH3H'&CC>L/?7LTB7UI[5[
MS=TY#:I[#];7H7KV<1TM2A]T^_U;TJ-"QWEU34HZ=H=4'KS2G2WNG[CS4&I4
MSW ]&M3^,V>TS>M0/42!Z-D^EU];B_J&Z'(/"5WNK>0>[E _\5"QM8\8I[,5
M<:%.C>G#K:D##6>MF%N1E6$]_C+X<+J=^CQ9WA%X.)9NW,)M3*X^M5(1_9H
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M+=98NX6()Z;J:+>RC"REZ$C]A@P)0=DFD5.N7T%F0TWOI7^9Q'XWL*31F I
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M?$I'5DY'+@T0]MGO;L=YY:V=PT5!2W9[#Y*>1.JCQ:,:4B18.1+4?=Y#^Z<
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M:%.H+VXS:8JRAI0RI90II4RC*%,JJ,YO&5>2*M[*$H30T"I,<FZB2B2" @?
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M=2/V,,N,\?\$<$&PM<+A&%_+B @*> 8G&?B>;]C"MN*@UU!LD[<%,AFMEAO
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M7 'RV\/EG_#PIG%W^_W_ U!+ P04    " "-A613*AZ>:#42   J/0  $0
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MJE<6'8J <--X2HI/%KP#%<@V/)$Q99JBPJ-JKFQQ<)A,[6RZ])A1Y!&U? ;
M*?!8OVJ)Z9 ?CB+/Z9@++AX%(:4_&9 6AX>ND8J930^, +_JZG-(TA*?45J3
M(D.;![$\50-\>Y<1/\X)4$-M031V'8+GT._:L!T2G@%0)5X^!F6([1G*EN\M
MZ)HB'0('"[V*_@^1M3R*N/HTK*6[&(*>?&OKCF:%JM=KU:5;%)3?_8Z@7US%
M%=4')Y>T0/?U+$X7;A:$EXJ+E%H%ZX-3=@DA0+&JJX\ND(D#B5+_O^54<GW3
M)<*'$L=UPJH!Q)1@;?7 J/3) G"Y2!OY>JO<63RV,5N<*MGI$Y7LFLE%U>9@
M=AL.QI[VW;=\_^(?8'2\Y/_I+/S+35^"$HHFNL;F+$6] 4=0J$F$^CU80B#;
M8BR[81C/Y9SM]M%2E>G(7R^:3PD&IRMT),(DOD#JY0F*%41L#^%N(M2.73BH
M<HO3ZW67GFJ\L7DW+:^5FPRVRZO;SJ@DQIERCC!T:JF,:[BJEJ[SC\NKPV*)
M(5@EM>$(!T>,[I!T:F ^T6BWW6@S BE'436$?GN--C\-N-2)ZU1W=MI[VZ_V
MMWL?^6F >Q#0+/O![_6;_N7R]>()V;"A2W'LK8&[G%HO'I9V>[5]=+"VV_+U
M5>P3P&45L8I5*I)P&K-5?U:1PGN_7K,=FX7-<B@-1XI[WO(KMMLI;"=63>?M
MX8W@K4#!)GV'B%=S[EW>P2_7H;50+N:AQ==&[^,FF>=@N]VFBZ0+ *HE/B 2
MX 0/H Q5//;]8(3";[E.;'%1KE>O\8)(I^W.X:MM\O(S%K^Y[?=OTLKTZ@T
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M.3 S.60X:RYH=&U02P$"% ,4    " "-A613'\ZU:.2W   Y!P4 $
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H82TR,#(Q,3$P,E]P<F4N>&UL4$L%!@     &  8 ?@$  "ON      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
